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A B S T R A C T
Background
Observational studies suggest higher pregnancy rates after the hysteroscopic removal of endometrial polyps, submucous fibroids, uterine
septum or intrauterine adhesions, which are detectable in 10% to 15% of women seeking treatment for subfertility.
Objectives
To assess the effects of the hysteroscopic removal of endometrial polyps, submucous fibroids, uterine septum or intrauterine adhesions
suspected on ultrasound, hysterosalpingography, diagnostic hysteroscopy or any combination of thesemethods inwomenwith otherwise
unexplained subfertility or prior to intrauterine insemination (IUI), in vitro fertilisation (IVF) or intracytoplasmic sperm injection
(ICSI).
Search methods
We searched theCochraneMenstrual Disorders and Subfertility SpecialisedRegister (8 September 2014), theCochrane Central Register
of Controlled Trials (The Cochrane Library 2014, Issue 9), MEDLINE (1950 to 12 October 2014), EMBASE (inception to 12 October
2014), CINAHL (inception to 11 October 2014) and other electronic sources of trials including trial registers, sources of unpublished
literature and reference lists. We handsearched the American Society for Reproductive Medicine (ASRM) conference abstracts and
proceedings (from January 2013 to October 2014) and we contacted experts in the field.
Selection criteria
Randomised comparisons between operative hysteroscopy versus control in women with otherwise unexplained subfertility or under-
going IUI, IVF or ICSI and suspected major uterine cavity abnormalities diagnosed by ultrasonography, saline infusion/gel instillation
sonography, hysterosalpingography, diagnostic hysteroscopy or any combination of these methods. Primary outcomes were live birth
and hysteroscopy complications. Secondary outcomes were pregnancy and miscarriage.
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Data collection and analysis
Two review authors independently assessed studies for inclusion and risk of bias, and extracted data. We contacted study authors for
additional information.
Main results
We retrieved 12 randomised trials possibly addressing the research questions. Only two studies (309 women) met the inclusion
criteria. Neither reported the primary outcomes of live birth or procedure related complications. In women with otherwise unexplained
subfertility and submucous fibroids there was no conclusive evidence of a difference between the intervention group treated with
hysteroscopic myomectomy and the control group having regular fertility-oriented intercourse during 12 months for the outcome of
clinical pregnancy. A large clinical benefit with hysteroscopic myomectomy cannot be excluded: if 21% of women with fibroids achieve
a clinical pregnancy having timed intercourse only, the evidence suggests that 39% of women (95% CI 21% to 58%) will achieve
a successful outcome following the hysteroscopic removal of the fibroids (odds ratio (OR) 2.44, 95% confidence interval (CI) 0.97
to 6.17, P = 0.06, 94 women, very low quality evidence). There is no evidence of a difference between the comparison groups for the
outcome of miscarriage (OR 0.58, 95% CI 0.12 to 2.85, P = 0.50, 30 clinical pregnancies in 94 women, very low quality evidence). The
hysteroscopic removal of polyps prior to IUI can increase the chance of a clinical pregnancy compared to simple diagnostic hysteroscopy
and polyp biopsy: if 28% of women achieve a clinical pregnancy with a simple diagnostic hysteroscopy, the evidence suggests that 63%
of women (95% CI 50% to 76%) will achieve a clinical pregnancy after the hysteroscopic removal of the endometrial polyps (OR 4.41,
95% CI 2.45 to 7.96, P < 0.00001, 204 women, moderate quality evidence).
Authors’ conclusions
A large benefit with the hysteroscopic removal of submucous fibroids for improving the chance of clinical pregnancy in women with
otherwise unexplained subfertility cannot be excluded. The hysteroscopic removal of endometrial polyps suspected on ultrasound in
women prior to IUI may increase the clinical pregnancy rate. More randomised studies are needed to substantiate the effectiveness of
the hysteroscopic removal of suspected endometrial polyps, submucous fibroids, uterine septum or intrauterine adhesions in women
with unexplained subfertility or prior to IUI, IVF or ICSI.
P L A I N L A N G U A G E S U M M A R Y
Hysteroscopy for treating suspected abnormalities of the cavity of the womb in women having difficulty becoming pregnant
Review question
Cochrane authors reviewed the evidence about the effect of the hysteroscopic treatment of suspected abnormalities of the cavity of the
womb in women having difficulty becoming pregnant.
Background
Human life starts when a fertilised egg has successfully implanted in the inner layer of the cavity of the womb. It is believed that
abnormalities originating from this site, such as polyps, fibroids, septa or adhesions, may disturb this important event. The removal
of these abnormalities by doing a hysteroscopy using a very small diameter inspecting device might therefore increase the chance of
becoming pregnant either spontaneously or after specialised fertility treatment, such as insemination or in vitro fertilisation.
Study characteristics
We found only two studies in 309 women. The first study compared the removal of fibroids versus no removal in 94 women wishing to
become pregnant from January 1998 until April 2005. The second study compared the removal of polyps versus simple hysteroscopy
only in 215 women before insemination with husband’s sperm from January 2000 to February 2004. The evidence is current to
September 2014. No study reported funding sources.
Key results
None of the studies reported live birth.
The study on the removal of fibroids in women with unexplained infertility suggests does not exclude a higher chance of conceiving
after surgery compared to regular sexual intercourse for 12 months. However uncertainty remains because the number of women (94)
and the number of pregnancies (30) are too small for any differences between both comparison groups to reach statistical significance.
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If 21% of women with fibroids achieve a pregnancy having timed intercourse only, the evidence suggests that between 21% to 58% of
women will achieve a successful outcome following the hysteroscopic removal of the fibroids.
The second study on the hysteroscopic removal of polyps supports a benefit with the hysteroscopic removal of polyps. If 28% of women
become pregnant in the control group, the evidence suggests that between 50% to 76% of women will become pregnant after the
removal of the endometrial polyps
No study reported data on adverse procedure related events.
More studies are needed before hysteroscopy can be proposed as a fertility-enhancing procedure in the general population of women
having difficulty becoming pregnant.
Quality of the evidence
The quality of the evidence on fibroids is very low: there was only one poorly conducted study lacking sufficient data.
The quality of the evidence on polyps is moderate: there were issues with selective reporting of outcomes.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Operative hysteroscopy compared with control for unexplained subfertility associated with suspected major uterine cavity abnormalities
Patient or population: women with submucous fibroids and otherwise unexplained subfertility
Settings: infertility centre in Rome, Italy
Intervention: hysteroscopic removal of one submucous fibroid ≤ 40 mm
Comparison: regular fertility-oriented intercourse
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Myomectomy
Live birth No data were reported for this primary outcome.
Hysteroscopy complica-
tions
No data were reported for this primary outcome.
Clinical pregnancy
ultrasound1
12 months
Medium-risk population OR 2.44
(0.97 to 6.17)
94
(1 study)
⊕©©©
very low2,3,4
214 per 1000 399 per 1000
(209 to 627)
Miscarriage
ultrasound5
12 months
Medium-risk population OR 0.58
(0.12 to 2.8)
30 pregnancies in 94
women
(1 study)
⊕©©©
very low2,3,4
556 per 1000 421 per 1000
(131 to 778)
*The basis for the assumed risk is the control group risk of the single included study (Casini 2006). The corresponding risk (and its 95% confidence interval) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 A clinical pregnancy was defined by the visualisation of an embryo with cardiac activity at six to seven weeks’ gestational age.
2 Unclear allocation concealment.
3 Wide confidence intervals.
4 High risk of selective outcome reporting and unclear whether there is other bias caused by imbalance in the baseline characteristics.
5 Miscarriage was defined by the clinical loss of an intrauterine pregnancy between the 7th and 12th weeks of gestation.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Subfertility is “a disease of the reproductive system defined by
the failure to achieve a clinical pregnancy after 12 months or
more of regular unprotected sexual intercourse” according to
the International Committee for Monitoring Assisted Reproduc-
tive Technology (ICMART) and the World Health Organiza-
tion (WHO) revised glossary of assisted reproductive technology
(ART) (Zegers-Hochschild 2009) (see: http://www.icmartivf.org/
ivf-glossary.html). It is estimated that 72.4millionwomen are sub-
fertile and that 40.5 million of these are currently seeking fertility
treatment (Boivin 2007). Unexplained subfertility usually refers to
a diagnosis (or lack of diagnosis) made in couples in whom all the
standard investigations such as tests of ovulation, tubal patency
and semen analysis are normal: it can be found in as many as 30%
to 40% of subfertile couples (Ray 2012).
The evaluation of the uterine cavity seems a basic step in the in-
vestigation of all subfertile women since the uterine cavity and its
inner layer, the endometrium, are assumed to be important for
the implantation of the human embryo, called a blastocyst. Nev-
ertheless, the complex mechanisms leading to successful implan-
tation are still poorly understood (Taylor 2008). Despite the huge
investment in research and developments of the technologies and
biology involved in medically assisted reproduction (MAR), the
maximum implantation rate per embryo transferred still remains
only 30% (Andersen 2008). The different phases of the implanta-
tion process are established by the complex interchange between
the blastocyst and the endometrium (Singh 2011).
Major uterine cavity abnormalities can be found in 10% to 15%
of women seeking treatment for subfertility; they usually consist
of the presence of excessive normal uterine tissue (Wallach 1972).
The most common acquired uterine cavity abnormality is an en-
dometrial polyp. This benign, endometrial stalk-like mass pro-
trudes into the uterine cavity and has its own vascular supply. De-
pending on the population under study and the applied diagnostic
test, endometrial polyps can be found in 1% to 41% of the subfer-
tile population (Silberstein 2006). A fibroid is an excessive growth
originating from the muscular part of the uterine cavity. Fibroids
are present in 2.4% of subfertile women without any other obvi-
ous cause of subfertility (Donnez 2002). A submucous fibroid is
located underneath the endometrium and is thought to interfere
with fertility by deforming the uterine cavity. Intrauterine adhe-
sions are fibrous tissue strings connecting parts of the uterine wall.
They are commonly caused by inflammation or iatrogenic tissue
damage (meaning involuntarily caused by a physician’s interven-
tion, for example an aspiration curettage after miscarriage) and
are present in 0.3% to 14% of subfertile women (Fatemi 2010).
A septate uterus is a congenital malformation in which the longi-
tudinal band separating the left and right Müllerian ducts, which
form the uterus in the human female fetus, has not been entirely
resorbed. A uterine septum is present in 1% to 3.6% of women
with otherwise unexplained subfertility (Saravelos 2008).
Ultrasonography (US), preferably transvaginally (TVS), is used to
screen for possible endometrium or uterine cavity abnormalities in
the work-up of subfertile women. This evaluation can be expanded
with hysterosalpingography (HSG), saline infusion/gel instillation
sonography (SIS/GIS) and diagnostic hysteroscopy. Diagnostic
hysteroscopy is generally considered as being the gold standard
procedure for the assessment of the uterine cavity since it enables
direct visualisation; moreover, treatment of intrauterine pathology
can be done in the same setting (Bettocchi 2004). Nevertheless,
even for experienced gynaecologists the hysteroscopic diagnosis of
themajor uterine cavity abnormalities may be problematic (Kasius
2011a).
Description of the intervention
Hysteroscopy is performed for the evaluation, or for the treat-
ment of the uterine cavity, tubal ostia and endocervical canal in
women with uterine bleeding disorders, Müllerian tract anoma-
lies, retained intrauterine contraceptives or other foreign bodies,
retained products of conception, desire for sterilisation, recurrent
miscarriage and subfertility. If the procedure is intended for evalu-
ating the uterine cavity only, it is called a diagnostic hysteroscopy.
If the observed pathology requires further treatment, the proce-
dure is called an operative hysteroscopy. In everyday practice, a
diagnostic hysteroscopy confirming the presence of pathology will
be followed by an operative hysteroscopy in a symptomatic pa-
tient.
Hysteroscopy allows the direct visualisation of the uterine cavity
through a rigid, semi-rigid or flexible endoscope. The hystero-
scope consists of a rigid telescope with a proximal eyepiece and
a distal objective lens that may be angled at 0° to allow direct
viewing or offset at various angles to provide a fore-oblique view.
Advances in fibreoptic technology have led to the miniaturisation
of the telescopes without compromising the image quality. The
total working diameters of modern diagnostic hysteroscopes are
typically 2.5 to 4.0mm.Operative hysteroscopy requires adequate
visualisation through a continuous fluid circulation using an in-
and an outflow channel. The outer diameters of modern operative
hysteroscopes have been reduced to a diameter between 4.0 and
5.5 mm. The sheath system contains one or two 1.6 to 2.0 mm
working channels for the insertion of small grasping or biopsy for-
ceps, scissors, myoma fixation instruments, retraction loops, mor-
cellators (surgical instruments used to divide and remove tissue
during endoscopic surgery) and aspiration cannulae, or unipolar
or bipolar electrodiathermy instruments.
Most diagnostic and many operative procedures can be done in an
office setting using local anaesthesia and fluid distension media,
while more complex procedures are generally performed as day
surgery under general anaesthesia (Clark 2005). Operative hys-
teroscopic procedures require a complex instrumentation set-up,
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special training of the surgeon and appropriate knowledge and
management of complications (Campo 1999).
Although complications from hysteroscopy are rare, they can be
potentially life threatening. A multicentre study including 13,600
diagnostic and operative hysteroscopic procedures performed in
82 centres reported a complication rate of 0.28%. Diagnostic hys-
teroscopy had a significantly lower complication rate compared to
operative hysteroscopy (0.13% versus 0.95%). Themost common
complicationof both types of hysteroscopywas uterine perforation
(0.13% for diagnostic; 0.76% for operative hysteroscopy). Fluid
intravasation occurred almost exclusively in operative procedures
(0.02%). Intrauterine adhesiolysis was associated with the highest
incidence of complications (4.5%); all of the other procedures had
complication rates of less than 1% (Jansen 2000).
How the intervention might work
It is assumed that major uterine cavity abnormalities may interfere
with factors that regulate the blastocyst-endometrium interplay,
for example hormones and cytokines, precluding the possibility of
pregnancy. Many hypotheses have been formulated in the litera-
ture of how endometrial polyps (Shokeir 2004; Silberstein 2006;
Taylor 2008; Yanaihara 2008), submucous fibroids (Pritts 2001;
Somigliana 2007; Taylor 2008), intrauterine adhesions (Yu 2008)
and uterine septum (Fedele 1996) are likely to disturb the implan-
tation of the human embryo; nevertheless, the precise mechanisms
of action through which each one of these major uterine cavity
abnormalities affects this essential reproductive process are poorly
understood. The fetal-maternal conflict hypothesis tries to explain
how a successful pregnancy may establish itself despite the intrin-
sic genomic instability of human embryos through the specialist
functions of the endometrium, in particular its capacity for cyclic
spontaneous decidualisation, shedding and regeneration. An ex-
cellent in-depth review linking basic research of human implanta-
tion with clinical practice can be found elsewhere (Lucas 2013).
For endometrial polyps, submucous fibroids, intrauterine adhe-
sions and uterine septum, observational studies have shown a clear
improvement in the spontaneous pregnancy rate after the hystero-
scopic removal of the abnormality (Taylor 2008). The chance for
pregnancy is significantly lower in subfertile women with submu-
cous fibroids compared to other causes of subfertility according
to a systematic review and meta-analysis of 11 observational stud-
ies (Pritts 2001; Pritts 2009). Three observational studies found
a major benefit for removing a uterine septum by hysteroscopic
metroplasty in subfertile women with a uterine septum (Mollo
2009; Shokeir 2011; Toma evi 2010).
Why it is important to do this review
A National Institute for Health and Clinical Excellence (NICE)
guideline on fertility assessment and treatment states that “women
should not be offered hysteroscopy on its own as part of the initial
investigation unless clinically indicated because the effectiveness
of surgical treatment of uterine abnormalities on improving preg-
nancy rates has not been established” (NICE 2004). There is, how-
ever, a trend in reproductive medicine that is developing towards
diagnosis and treatment of all major uterine cavity abnormalities
prior to fertility treatment. This evolution can be explained by
three reasons. Firstly, diagnostic hysteroscopy is generally accepted
in everyday clinical practice as the ‘gold standard’ for identifying
uterine abnormalities because it allows direct visualisation of the
uterine cavity (Golan 1996). Secondly, since 2004 several ran-
domised controlled trials (RCTs) have demonstrated the techni-
cal feasibility and the high patient satisfaction rate in women un-
dergoing both diagnostic and operative hysteroscopy for various
reasons including subfertility (Campo 2005; De Placido 2007;
Garbin 2006; Guida 2006; Kabli 2008; Marsh 2004; Sagiv 2006;
Shankar 2004; Sharma 2005). Thirdly, in a subfertile population
screened systematically by diagnostic hysteroscopy, the incidence
of newly detected intrauterine pathology may be as high as 50%
(Campo 1999; De Placido 2007).
This review aims to summarise and critically appraise the cur-
rent evidence on the effectiveness of operative hysteroscopic in-
terventions in subfertile women with major uterine cavity abnor-
malities, both in women with unexplained subfertility and those
bound to undergo MAR. Since uterine cavity abnormalities may
negatively affect the uterine environment, and therefore the like-
lihood of conceiving (Rogers 1986), it has been recommended
that these abnormalities be diagnosed and treated by hysteroscopy
to improve the cost-effectiveness in subfertile women undergoing
MAR, where recurrent implantation failure is inevitably associated
with a higher economic burden to society.
The study of the association between subfertility and major uter-
ine cavity abnormalities might increase our current understanding
of the complex mechanisms of human embryo implantation. This
could lead to the development of cost-effective strategies in re-
productive medicine with benefits for both the individual woman
suffering from subfertility associated with major uterine cavity ab-
normalities as well as for society, in a broader perspective.
O B J E C T I V E S
To assess the effects of the hysteroscopic removal of endometrial
polyps, submucous fibroids, uterine septum or intrauterine adhe-
sions suspected on ultrasound, hysterosalpingography, diagnostic
hysteroscopy or any combination of thesemethods in women with
otherwise unexplained subfertility or prior to intrauterine insemi-
nation (IUI), in vitro fertilisation (IVF) or intracytoplasmic sperm
injection (ICSI).
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Inclusion criteria
• Only trials that were either clearly randomised or claimed
to be randomised and did not have evidence of inadequate
sequence generation such as date of birth or hospital number
were eligible for inclusion.
• Cluster trials were considered to be eligible if the
individually randomised women were the unit of analysis.
• Cross-over trials were also considered to be eligible for
completeness but we planned to use only pre-cross-over data for
meta-analysis.
Exclusion criteria
• Quasi-randomised trials.
Types of participants
Inclusion criteria
• Women of reproductive age with otherwise unexplained
subfertility and endometrial polyps, submucous fibroids, septate
uterus or intrauterine adhesions detected by US, SIS, GIS, HSG,
diagnostic hysteroscopy or any combination of these methods.
Besides unexplained subfertility as the main clinical problem,
other gynaecological complaints, such as pain or bleeding, might
or might not be present.
• Women of reproductive age with subfertility, undergoing
IUI, IVF or ICSI with endometrial polyps, submucous fibroids,
septate uterus or intrauterine adhesions detected by US, SIS,
GIS, HSG, diagnostic hysteroscopy or any combination of these
methods.
Exclusion criteria
• Women of reproductive age with subfertility and
intrauterine cavity abnormalities other than endometrial polyps,
submucous fibroids, intrauterine adhesions and septate uterus,
e.g. subserous or intramural fibroids without cavity deformation
on hysteroscopy, acute or chronic endometritis, adenomyosis or
other so-called ’subtle focal’ lesions.
• Women of reproductive age with endometrial polyps,
submucous fibroids, intrauterine adhesions or septate uterus
without subfertility.
• Women of reproductive age with recurrent pregnancy loss.
Types of interventions
Two types of randomised interventions were addressed; within
both comparisons the suspected major uterine cavity abnormali-
ties were stratified into endometrial polyps, submucous fibroids,
uterine septum and intrauterine adhesions. For the second com-
parison there was a stratification into IUI, IVF or ICSI.
• Randomised comparison between operative hysteroscopy
versus control in women with otherwise unexplained subfertility
and suspected major uterine cavity abnormalities diagnosed by
US, SIS, GIS, HSG, diagnostic hysteroscopy or any combination
of these methods.
• Randomised comparison between operative hysteroscopy
versus control in women undergoing IUI, IVF or ICSI with
suspected major uterine cavity abnormalities diagnosed by US,
SIS, GIS, HSG, diagnostic hysteroscopy or any combination of
these methods.
Types of outcome measures
Primary outcomes
1. Effectiveness: live birth, defined as a delivery of a live fetus after
20 completed weeks of gestational age that resulted in at least one
live baby born. The delivery of a singleton, twin or multiple preg-
nancy was counted as one live birth (Zegers-Hochschild 2009).
2. Adverse events: hysteroscopy complications, defined as any
complication due to hysteroscopy.
Secondary outcomes
3. Pregnancy
• Ongoing pregnancy, defined as a pregnancy surpassing the
first trimester or 12 weeks of pregnancy.
• Clinical pregnancy with fetal heart beat, defined as a
pregnancy diagnosed by US or clinical documentation of at least
one fetus with a heart beat (Zegers-Hochschild 2009).
• Clinical pregnancy, defined as a pregnancy diagnosed by US
visualisation of one or more gestational sacs or definitive clinical
signs of pregnancy (Zegers-Hochschild 2009).
4. Adverse events: miscarriage, defined as the spontaneous loss of
a clinical pregnancy before 20 completed weeks of gestation, or if
gestational age is unknown a fetus with a weight of 400 g or less
(Zegers-Hochschild 2009).
We planned to report the minimally important clinical difference
(MICD) for the primary outcome of live birth. AMICD of 5% for
the live birth rate was predefined as being relevant for the benefits.
The imputation of this value was based on data from a clinical
decision analysis on screening hysteroscopy prior to IVF (Kasius
2011b).
We planned to include the main outcome measures ’live birth’,
’hysteroscopy complications’ and ’miscarriage’ in a ’Summary of
findings’ table. The ’Summary of findings’ table was generated
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using GRADEpro software (GRADE profiler version 3.6). This
table evaluates the overall quality of the body of evidence for the
main review outcomes, using GRADE criteria (study limitations
(i.e. risk of bias), consistency of effect, imprecision, indirectness
and publication bias). We justified, documented and incorporated
judgements about evidence quality (high, moderate, low or very
low) into the reporting of results for each outcome (Summary of
findings for the main comparison; Summary of findings 2).
See the methods section of the protocol of this Cochrane review
published in the Cochrane Database of Systematic Reviews (Bosteels
2011).
GRADE profiler version 3.6: See: https://tech.cochrane.org/
revman/other-resources/gradepro/download.
Search methods for identification of studies
See the Cochrane Menstrual Disorders and Subfertility Group
(MDSG) for methods used in reviews, as stated in the MDSG
Module.
See also the methods section of the protocol for this Cochrane
review published in the Cochrane Database of Systematic Reviews
(Bosteels 2011).
An experienced librarian at the Biomedical Library Gasthuisberg
of the Catholic University of Leuven (Jens De Groot) developed
the literature search strategy in liaison with the MDSG Trials
Search Co-ordinator (Marian Showell).
Two review authors (JB and JK) independently performed a
comprehensive search of all published and unpublished reports
that described hysteroscopy in subfertile women with endome-
trial polyps, submucous fibroids, intrauterine adhesions or septate
uterus, or undergoing MAR. The search strategy was not limited
by language, year of publication or document format. All the re-
trieved citations from MEDLINE, EMBASE, WoS, CENTRAL,
the MDSG Specialised Register, BIOSIS PREVIEWS and hand-
search-related articles were merged and duplicates removed using
specialised software (EndNote Web 3.5 - last done on 14 October
2014).
EndNote Web: See: http://www.myendnoteweb.com/
EndNoteWeb.html.
Electronic searches
We searched the following bibliographic databases, trial registers
and web sites: the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2014, Issue 9) (Appendix 1),
the Menstrual Disorders and Subfertility Group (MDSG) Spe-
cialised Register (8 September 2014) (Appendix 2), MEDLINE
using PubMed (1950 to 12 October 2014) (Appendix 3) and
EMBASE using EMBASE.com (inception to 12 October 2014)
(Appendix 4).
The search strategy combined both index and free-text terms.
Our MEDLINE search included the Cochrane highly sensitive
search strategy for identifying randomised trials using the PubMed
format which appears in the Cochrane Handbook for Systematic
Reviews of Interventions (version 5.1.0, Chapter 6, 6.4.11.1 - box
6.4.a) (Higgins 2011).
Our EMBASE search included the SIGN trial filter developed by
the Scottish Intercollegiate Guidelines Network (www.sign.ac.uk/
methodology/filters.html#random).
Other electronic sources of trials were:
• Cochrane Database of Systematic Reviews (CDSR) in The
Cochrane Library 2014, Issue 9 for published reviews to check for
references to the included and excluded studies.
• Database of Abstracts of Reviews of Effectiveness (DARE)
and the Health Technology Assessment Database (HTA
Database) through the Centre for Reviews and Dissemination
(from inception to 12 October 2014) (www.crd.york.ac.uk).
• National Guideline Clearinghouse (www.guideline.gov) for
evidence-based guidelines (from inception to 12 October 2014).
• BIOSIS previews through ISI Web of Knowledge (http://
isiwebofknowledge.com) and CINAHL (www.cinahl.com)
through EBSCOHOST available at the Biomedical Library
Gasthuisberg of the Catholic University of Leuven (from
inception to 11 October 2014) (Appendix 5).
• Trial registers for ongoing and registered trials: ’Current
Controlled Trials’ (www.controlled-trials.com),
’ClinicalTrials.gov’ provided by the US National Institutes of
Health (http://clinicaltrials.gov/ct2/home) and the World
Health Organization International Clinical Trials Registry
Platform search portal (http://apps.who.int/trialsearch/) (from
inception to 12 October 2014).
• Citation indexes: Science Citation Index through Web of
Science (http://scientific.thomson.com/products/sci/) - SCI-
EXPANDED (1955 to 11 October 2014) and Conference
Proceedings Citation Index - Science (CPCI-S) (1990 to 11
October 2014) and Scopus available at the Biomedical Library
Gasthuisberg of the Catholic University of Leuven) (from
inception to 12 October 2014).
• Conference abstracts and proceedings on the ISI Web of
Knowledge (http://isiwebofknowledge.com) applying ’SCI-
EXPANDED’ (1955 to 11 October 2014) and ’CPCI-S’ (1990
to 11 October 2014) (Appendix 6).
• LILACS database, which is a source of trials from the
Spanish and Portuguese speaking world (http://bases.bireme.br/
cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&
base=LILACS&lang=i&form=F) (from inception to 11 October
2014).
• European grey literature through Open Grey database
(from inception to 11 October 2014) (http://www.opengrey.eu/
subjects/).
• General search engines: Turning Research into Practice
(TRIP) database (www.tripdatabase.com), Google Scholar (
http://scholar.google.be/advanced_scholar_search) and Scirus (
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http://www.scirus.com) (from inception to 11 October 2014).
Searching other resources
Two review authors (JB and JK) independently handsearched the
reference lists of reviews, guidelines, included and excluded studies
and other related articles for additional eligible studies. JB con-
tacted the first or corresponding authors of included studies to
ascertain if they were aware of any ongoing or unpublished trials.
We handsearched the American Society for Reproductive
Medicine (ASRM) conference abstracts and proceedings (from
January 2013 to 12 October 2014) independently (JB and JK)
since these were not covered in the MDSG register (after consul-
tation with the MDSG Trials Search Co-ordinator).
JB contacted European experts and opinion leaders in the field of
hysteroscopic surgery through a formalised project approved by
the Board of the European Society of Gynaecological Endoscopy
(ESGE) to ascertain if these experts were aware of any relevant
published or unpublished studies.
Data collection and analysis
Selection of studies
Two review authors were responsible for independently selecting
the studies (FB and TD). We scanned titles and abstracts from
the searches and obtained the full text of those articles that ap-
peared to be eligible for inclusion. We linked multiple reports of
the same study together while citing all the references and indicat-
ing the primary reference of the identified study. On assessment,
we categorised the trials as ’included studies’ (Characteristics of
included studies), ’excluded studies’ (Characteristics of excluded
studies), ’ongoing studies’ (Characteristics of ongoing studies) or
’studies awaiting classification’ (Characteristics of studies awaiting
classification). Any disagreements between both review authors
who are content experts were resolved through consensus or by
a third review author with methodological expertise (BWM). We
contacted the first or corresponding authors of the primary study
reports for further clarification when required. If disagreements
between review authors were not resolved, we categorised the stud-
ies as ’awaiting classification’ and the disagreement was reported
in the final review. We avoided the exclusion of studies on the
basis of the reported outcome measures throughout the selection
phase by searching all potential eligible studies that could have
measured the primary or secondary outcomes even if these were
not reported. We appraised studies in an unblinded fashion, as
recommended by the Cochrane Menstrual Disorders and Subfer-
tility Review Group.
Data extraction and management
Two review authors, one methodologist (JB) and one topic area
specialist (SW), independently assessed the studies that appeared
to meet the inclusion criteria by using data extraction forms
based on the items listed in the protocol of this Cochrane review
(Appendix 7). We pilot-tested the data extraction form and pro-
cess by reviewing 10 randomly chosen study reports. In the pilot
phase one retracted record (Shokeir 2011) was consistently iden-
tified by the two review authors on the basis of finding duplicated
parts from another study included in the present Cochrane review
(Pérez-Medina 2005). For studies with multiple publications, we
used themain trial report as the primary data extraction source and
additional details supplemented from secondary papers if appli-
cable. JB contacted the first or corresponding authors of the orig-
inal studies to obtain clarification whenever additional informa-
tion on trial methodology or original trial data was required. We
sent reminder correspondence if a reply was not obtained within
two weeks. The two review authors resolved any discrepancies in
opinion by discussion; they searched for arbitration by a third re-
view author if consensus was not reached (BWM). BWM resolved
disagreements which could not be resolved by the review authors
after contacting the first or corresponding authors of the primary
study reports. If this failed, the disagreement was reported in the
review.
Assessment of risk of bias in included studies
Two authors (JB and SW) independently assessed the risk of bias
of the included studies by using the Cochrane ’Risk of bias’ as-
sessment tool that considers the following criteria, listed in the
Cochrane Handbook for Systematic Reviews of Interventions (version
5.1.0, Chapter 8, table 8.5.a and 8.5.b) (Higgins 2011): random
sequence generation; allocation concealment; blinding of partic-
ipants and personnel; blinding of outcome assessors; complete-
ness of outcome data; selective outcome reporting; other potential
sources of bias. We assessed all six criteria in the Cochrane ’Risk
of bias’ tool; any disagreements were resolved by consensus or by
discussion with a third review author (BWM). We fully described
all judgements. The conclusions were presented in the ’Risk of
bias’ table (Characteristics of included studies) and incorporated
into the interpretation of review findings by means of sensitivity
analyses.
We presented a narrative description of the quality of evidence
which is necessary for the interpretation of the results of the review
and which is based on the review authors’ judgements on the risk
of bias of the included trials (Quality of the evidence).
Measures of treatment effect
For the dichotomous data for live birth, pregnancy,miscarriage and
hysteroscopy complications, we used the numbers of events in the
control and intervention groups of each study to calculateMantel-
Haenszel (M-H) odds ratios (OR). We presented 95% confidence
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intervals (95% CI) for all outcomes. The OR has mathematically
sound properties that are consistent with benefit or harm and
which work well inmost RCTs on the effectiveness of reproductive
surgery given that sample sizes are usually small and trial events are
rare. Where data to calculate ORs were not available, we planned
to utilise the most detailed numerical data available that might
facilitate similar analyses of included studies (e.g. test statistics, P
values). We have compared the magnitude and direction of effect
reported by studies with how they were presented in the review,
taking account of legitimate differences. We contacted the corre-
sponding or first authors of all included trials that reported data
in a form that was not suitable for meta-analysis, such as time-
to-pregnancy data (TTP). We planned to report the data of those
reports that failed to present additional data that could be analysed
under ’other data’; we have not included TTP data in any meta-
analysis.
Unit of analysis issues
All primary and secondary outcomes except miscarriage were ex-
pressed as per woman randomised; miscarriage was expressed as
per pregnancy. We planned to summarise reported data that did
not allow a valid analysis, such as ’per cycle’, in an additional
table without any attempt at meta-analysis. Multiple live births
and multiple pregnancies were counted as one live birth or one
pregnancy event.We planned including only first-phase data from
cross-over trials, if available.
Dealing with missing data
We aimed to analyse the data on an intention-to-treat basis. We
tried to obtain as much missing data as possible from the original
investigators. If this was not possible, we undertook imputation
of individual values for the primary outcomes only. We assumed
that live births would not have occurred in participants without
a reported primary outcome. For all other outcomes we analysed
only the available data. We subjected any imputation of missing
data for the primary outcomes to sensitivity analysis. If substantial
differences in the analysis were found as compared to an available
data analysis, we reported this in the final review.
Assessment of heterogeneity
We planned to consider whether the clinical and methodological
characteristics of the included studies were sufficiently similar for
meta-analysis to provide a clinically meaningful summary, if more
randomised studies were included. We planned to carry out a for-
mal assessment of statistical heterogeneity by using the I² statistic
combined with the Q-statistic. Cochran’s Q test, a kind of Chi²
statistic, is the classical measure to test significant heterogeneity.
Cochran’s Q test is calculated as the weighted sum of squared dif-
ferences between individual study effects and the pooled effect
across studies. The Q-statistic follows Chi² distribution with k-
1 degree of freedom where k is the number of studies. Q > k-1
suggests statistical heterogeneity. A low P value of Cochran’s Q test
means significant heterogeneous results among different studies;
usually, the P value at 0.10 is used as the cut-off. The Q-statistic
has low power as a comprehensive test of heterogeneity especially
when the number of studies is small. The Q-statistic informs us
about the presence or absence of heterogeneity; it does not report
on the extent of such heterogeneity. The I² statistic describes the
percentage of variation across studies that is due to significant het-
erogeneity rather than random chance. It measures the extent of
heterogeneity. An I² statistic greater than 50% was taken to indi-
cate substantial heterogeneity (Higgins 2003). We planned to ex-
plore possible explanations for heterogeneity by performing sensi-
tivity analyses in Review Manager 5 (RevMan 2011), if there was
evidence of substantial statistical heterogeneity.
Assessment of reporting biases
In view of the difficulty in detecting and correcting for publication
bias, reporting bias and within-study reporting bias, we planned
to minimise their potential impact by ensuring a comprehensive
search for eligible studies and by being alert in identifying dupli-
cation of data. We aimed to detect within-trial selective reporting
bias, such as trials failing to report obvious outcomes, or reporting
them in insufficient detail to allow inclusion. We planned to seek
published protocols and to compare the outcomes between the
protocol and the final published study report. Where identified
studies failed to report the primary outcomes (e.g. live birth), but
did report interim outcomes (e.g. pregnancy), we would have un-
dertaken informal assessment as towhether the interim values were
similar to those reported in studies that also reported the primary
outcomes. If there were outcomes defined in the protocol or the
study report with insufficient data to allow inclusion, the review
indicated this lack of data and suggested that further clinical trials
need to be conducted to clarify these knowledge gaps. If there were
10 or more studies, we planned to create a funnel plot to explore
the possibility of small study effects (a tendency for estimates of
the intervention effect to be more beneficial in smaller studies). A
gap on either side of the graph would have given a visual indication
that some trials had not been identified. Given the low number
of studies included in the final review, it was not possible to assess
reporting bias formally.
Data synthesis
Review author JB entered the data and carried out the statistical
analysis of the data using Review Manager 5 software. We con-
sidered the outcomes live birth and pregnancy to be positive and
higher numbers as a benefit. We considered the outcomes miscar-
riage and hysteroscopy complications in the protocol as negative
effects and higher numbers harmful. These aspects were taken into
consideration when assessing the summary graphs. In the quan-
titative synthesis an increase in the odds of a particular outcome,
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either beneficial or harmful, was displayed graphically to the right
of the centre-line and a decrease in the odds of an outcome to the
left of the centre-line.
We planned to combine data from primary studies in a meta-anal-
ysis with Review Manager 5 using the Peto method and a fixed-ef-
fect model (Higgins 2011) for the following comparisons, if more
randomised studies could have been included and if significant
clinical diversity and statistical heterogeneity could have been con-
fidently ruled out.
• Operative hysteroscopy versus control in women with
otherwise unexplained subfertility and suspected major uterine
cavity abnormalities diagnosed by US, SIS, GIS, HSG,
diagnostic hysteroscopy or any combination of these methods.
• Operative hysteroscopy versus control in women
undergoing MAR with suspected major uterine cavity
abnormalities diagnosed by US, SIS, GIS, HSG, diagnostic
hysteroscopy or any combination of these methods.
We planned to define analyses that were both comprehensive and
mutually exclusive so that all eligible study results were slotted into
one of the two predefined strata only. If no trials were retrieved for
some comparisons, the review indicated their absence identifying
knowledge gaps which need further research. Since meta-analysis
was not possible due to the limited number of studies included in
the review, we presented a narrative overview as pre-specified in
the protocol (Bosteels 2011).
Subgroup analysis and investigation of heterogeneity
We planned to carry out subgroup analyses to determine the sepa-
rate evidence within the following subgroups, if enough data were
available.
• Those studies that reported ’live birth’ and ’ongoing or
clinical pregnancy’ in order to assess any overestimation of effect
and reporting bias.
• For the two types of randomised comparison, stratified
according to the type of uterine abnormality, we planned to carry
out subgroup analyses according to the extent or severity of the
uterine abnormality. We used the length and diameter in
centimetres or calculated volumes of endometrial polyps and
submucous fibroids, the lengths and widths of uterine septa and
the European Society of Gynaecological Endoscopy (ESGE)
classification for intrauterine adhesions (Wamsteker 1998) as
references when applicable.
• We planned to carry out subgroup analyses based on the
modifier patient age if enough studies were available.
The interpretation of the statistical analysis for subgroups is not
without problems. In the final review we reported the interpreta-
tion of any subgroup analysis performed restrictively, if at all pos-
sible, and with utmost caution even if enough data were retrieved.
Sensitivity analysis
We aimed to perform sensitivity analyses for the primary outcomes
to determine whether the conclusions are robust to arbitrary de-
cisions made regarding the eligibility and analysis. These analyses
included consideration of whether conclusions would have dif-
fered if:
• eligibility were restricted to studies without high risk of bias;
• alternative imputation strategies were adopted;
• a random-effects rather than a fixed-effect model was
adopted;
• the summary effect measure was risk ratio rather than odds
ratio.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
Review authors JB and JK scanned the titles and abstracts of the
results of the search strings. There were 29 records from CEN-
TRAL, 180 records from theMDSG Specialised Register, 89 from
MEDLINE, 253 fromEMBASE and 70 fromWeb of Science. An
electronic search in DARE produced eight records; there were 15
guidelines from National Guideline Clearinghouse, eight records
from the metaRegister of controlled trials and 16 records from
WHO ICTRP. We identified 303 additional references in Scopus.
We identified 21 records inCINAHL.No records were retrieved in
LILACS and Open Grey. We handsearched 3085 abstracts in the
proceedings of the American Society for Reproductive Medicine;
no additional abstracts were identified after contacting the experts
of the European Society for Gynaecological Endoscopy (ESGE).
After combining 992 records identified from electronic searches
with 3085 additional records through searching other sources, we
screened 4077 records for duplicates by using a specialised soft-
ware program (EndNote Web). After the removal of 234 dupli-
cate references and 3097 records that were obviously irrelevant we
retrieved 43 potentially eligible studies. We excluded five studies
for being quasi- or not randomised (Characteristics of excluded
studies). We excluded one study (Shokeir 2010) because the study
report had been retracted at the request of the publisher. An-
other 25 studies were not included in the present Cochrane re-
view for not addressing the research questions (Characteristics
of excluded studies). We retrieved 12 possibly relevant studies:
two RCTs are awaiting classification (Characteristics of studies
awaiting classification) and eight are still ongoing (Characteristics
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of ongoing studies). We finally included two RCTs addressing
the research questions of this Cochrane review (Characteristics of
included studies).
See: PRISMA flow chart (Figure 1).
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Figure 1. PRISMA study flow diagram.
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Included studies
Study design and setting
Two parallel-design randomised controlled trials were included in
the review.
Both were single-centre studies, one conducted in Italy (Casini
2006) and the other in Spain (Pérez-Medina 2005).
Participants
One study (Casini 2006) included 94 women with submucous
fibroids with or without intramural fibroids and otherwise un-
explained subfertility. There were 52 women in the intervention
group and 42 women in the control group. The mean participant
age was 31 years (range 29 to 34) in the subgroup of women with
submucous fibroids only and 32 years (range 30 to 35) in the sub-
group of women with mixed intramural-submucous fibroids. All
women underwent a complete fertility assessment. Transvaginal
ultrasonography was performed in order to diagnose the presence
of uterine fibroids. All women who were found to be affected by
uterine fibroids excluding all other causes of infertility were asked
to participate in the study. Only women aged ≤ 35 years with a
problem of subfertility for at least one year and the presence of
one fibroid of diameter≤ 40mmwere selected for randomisation.
Patients older than 35 years or with other causes of infertility at
the performed examinations were excluded. Other exclusion cri-
teria were the presence of two or more fibroids of diameter > 40
mm, body weight > 20% of normal weight; and use of medication
containing oestrogens, progestins or androgens within eight weeks
prior to the study.
The second study (Pérez-Medina 2005) included 215womenwith
unexplained,male or female factor infertility for at least 24months
bound to undergo intrauterine insemination with a sonographic
diagnosis of endometrial polyps. There were 101 women in the in-
tervention group and 103 women in the control group; 11 women
were lost to follow-up, six in the intervention group and five in the
control group. The mean participant age was 31 years (range 27 to
35). All women suffered from primary subfertility; they all under-
went a complete fertility assessment. Unexplained infertility was
diagnosed in women with normal ovulatory cycles, semen analy-
sis, hysterosalpingography (HSG) and postcoital testing. Female
factor infertility was diagnosed in women with ovulatory dysfunc-
tion, cervical factor or endometriosis. Male factor infertility was
diagnosed if two semen analyses obtained at least one month apart
were subnormal according to theWHO criteria. The sonographic
diagnosis of endometrial polyps was established by the demon-
stration of the vascular stalk of the endometrial polyp by colour
Doppler in a hyperechogenic formation with regular contours oc-
cupying the uterine cavity, surrounded by a small hypoechogenic
halo. Women older than 39 years of age or with anovulation or
uncorrected tubal disease or previous unsuccessful use of recombi-
nant follicle stimulating hormone (FSH), as well as women with
a male partner with azoospermia, were excluded from randomisa-
tion.
Details of the inclusion and exclusion criteria are found in
Characteristics of included studies.
Interventions
In one trial (Casini 2006), the intervention group was treated with
hysteroscopic surgery to remove the fibroids; transvaginal ultra-
sonography was done three months after the procedure for con-
trol. Women in the intervention group were suggested to abstain
from having sexual intercourse for three months and then to start
having regular fertility-oriented intercourse. Women in the con-
trol group were asked to immediately start having regular fertility-
oriented intercourse. Both groups were monitored for up to 12
months after study commencement.
In the second trial (Pérez-Medina 2005), all hysteroscopic inter-
ventions were done in an outpatient office setting under local
anaesthesia by one gynaecologist. In the intervention group the en-
dometrial polyps suspected on Doppler ultrasound were extracted
by means of a rigid 1.5 mm scissors and forceps through the work-
ing channel of a 5.5 mm continuous flow hysteroscope. All re-
moved polyps were submitted for histopathological examination.
If resection was not possible during the outpatient hysteroscopy,
the woman was scheduled for operative hysteroscopy under spinal
anaesthesia in the operating theatre of the hospital. All the hystero-
scopic interventions were done in the follicular phase of the men-
strual cycle. The women of the intervention group were scheduled
to receive four cycles of intrauterine insemination (IUI), using
subcutaneous injections of FSH 50 IU (international units) daily
from the third day of the cycle.The first IUI treatment cycle was
started three cycles after the operative hysteroscopy. In the control
group, the endometrial polyps suspected on Doppler ultrasound
were left in place during diagnostic hysteroscopy using a 5.5 mm
continuous flow hysteroscope; polyp biopsy was performed to es-
tablish a histopathological diagnosis. All women in the control
group were scheduled to receive four cycles of IUI, using subcu-
taneous injections of FSH 50 IU daily from the third day of the
cycle. The first IUI treatment cycle was scheduled three cycles af-
ter the diagnostic hysteroscopy. Four IUI cycles were attempted
before finishing the trial.
Outcomes
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Neither of the two included studies reported data on the primary
outcomes for this review, live birth and hysteroscopy complication
rates.
The first trial (Casini 2006) measured two secondary outcomes,
clinical pregnancy and miscarriage rate. A clinical pregnancy was
defined by the visualisation of an embryo with cardiac activity at
six to seven weeks of pregnancy. Miscarriage was defined by the
loss of an intrauterine pregnancy between the seventh and 12th
weeks of gestation.
The second trial (Pérez-Medina 2005) reported only one sec-
ondary outcome, the clinical pregnancy rate. This was defined by
a pregnancy diagnosed by ultrasound visualisation of one or more
gestational sacs.
A plausible explanation for the failure to report on the live birth
rate was given by the study authors of one trial (Pérez-Medina
2005). They failed to give an explanation for the lack of data on
the other primary outcome, the hysteroscopy complication rate.
The study authors of the other trial (Casini 2006) could not be
contacted successfully for further clarification on the absence of
reporting the primary outcomes.
Excluded studies
We excluded 31 trials on hysteroscopic interventions for various
reasons.
One trial (Shokeir 2010) was excluded since the main pub-
lished report was retracted at the request of the editor of the
publishing journal as it duplicates parts of a paper on a dif-
ferent topic that had already appeared in another journal pub-
lished years before (Pérez-Medina 2005). One trial (Pabuccu
2008) is a quasi-randomised trial; four trials (De Angelis 2010;
Gao 2013; Mohammed 2014; Trnini -Pjevi 2011) are non-
randomised studies. We excluded 25 trials because they did
not address the pre-specified PICO (Participants, Interventions,
Comparisons andOutcomes) research questions of this Cochrane
review. Eight trials (Aghahosseini 2012; Demirol 2004; El-Nashar
2011; Elsetohy 2015; El-Toukhy 2009; Fatemi 2007; Rama Raju
2006; Shawki 2010) studied the effectiveness of hysteroscopy in
subfertile women bound to undergo in vitro fertilisation (IVF)
or intracytoplasmic sperm injection (ICSI) treatment with un-
suspected or no uterine cavity abnormalities. Three trials (Lieng
2010a; Muzii 2007; van Dongen 2008) were excluded because the
study population included women not of reproductive age suf-
fering from gynaecological problems other than subfertility. One
trial (Vercellini 1993) was excluded because the study population
included only women with repeated miscarriage. Nine trials (Abu
Rafea 2013; Acunzo 2003; Amer 2010; De Iaco 2003; Di Spiezio
Sardo 2011; Guida 2004; Lin 2014; Pansky 2009; Tonguc 2008)
studied the effectiveness of adjunctive therapies (hyaluronic acid
gel, amnion graft, balloon catheter, cyclical hormone replacement
therapy alone or intrauterine device alone or both co-treatments
combined) for the prevention of intrauterine adhesions following
hysteroscopic adhesiolysis. Four trials (Colacurci 2007; Darwish
2008; Parsanezhad 2006; Youssef 2013) compared different surgi-
cal techniques for treating uterine septum in a mixed study popu-
lation of women suffering from subfertility or recurrent pregnancy
loss.
See the table Characteristics of excluded studies.
Studies awaiting classification
Two trials are awaiting classification (Clark 2014; Moramezi
2012).
See the table Characteristics of studies awaiting classification.
Ongoing studies
Eight trials are ongoing (Abiri 2014; Basma 2013; Broekmans
2010; El-Khayat 2012;Hare 2013; Revel 2011; Sohrabvand 2012;
Weiss 2005).
See the table Characteristics of ongoing studies.
Risk of bias in included studies
See the ’Risk of bias’ summary for the review authors’ judgements
about each risk of bias item in the included study (Figure 2).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
See the ’Risk of bias’ graph for the review authors’ judgements
about each risk of bias item presented as percentages across the
two included studies (Figure 3).
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
We judged both studies included in the Cochrane review (Casini
2006; Pérez-Medina 2005) to be at low risk of selection bias re-
lated to random sequence generation, as both used computerised
random numbers tables.
We judged one study (Pérez-Medina 2005) to be at low risk for
selection bias related to allocation concealment, as sequentially
numbered, opaque, sealed envelopes were used to conceal the ran-
dom allocation of women to one of the comparison groups. We
judged the second trial (Casini 2006) to be at an unclear risk for
selection bias related to allocation concealment since the method
used was not reported and no further clarification by the authors
could be obtained.
Blinding
Originally we intended not to assess the ’Risk of bias’ items ’blind-
ing of participants and personnel’ and ’blinding of outcome as-
sessors’ for either of the two included studies as pre-specified-and
justified- in the published protocol for this review (see Bosteels
2011). The editorial reviewers insisted on assessing all six ’Risk
of bias’ items as stated in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We judged both studies
(Casini 2006; Pérez-Medina 2005) to be at unclear risk of perfor-
mance and detection bias since in both studies the methods for
blinding participants, personnel and outcome assessors were not
stated and no further clarification could be obtained.
Incomplete outcome data
We judged both studies included in the Cochrane review to
be at low risk of attrition bias. One study (Casini 2006) re-
ported outcome data of all randomised women. The second study
(Pérez-Medina 2005) analysed themajority of women randomised
(95%). The missing outcome data in the remaining 5% were bal-
anced in numbers with similar reasons for missing data between
the two comparison groups.
Selective reporting
We judged both studies included in the review (Casini 2006;
Pérez-Medina 2005) to be at high risk of reporting bias. Both
studies (Casini 2006; Pérez-Medina 2005) failed to include data
for the primary outcome live birth, which could reasonably have
been reported in studies conducted over a seven-year (Casini 2006)
and a four-year (Pérez-Medina 2005) period. Although a plau-
sible explanation was given by the contact author of one study
(Pérez-Medina 2005), we judged that it could have been possible
to obtain data on the live birth rates if the study authors had con-
tacted the referring gynaecologists (see Characteristics of included
studies). Moreover, no data on adverse outcomes such as mis-
carriage or hysteroscopy complications were reported in one trial
(Pérez-Medina 2005), whereas the second study reported miscar-
riage rates only for the adverse events (Casini 2006).
Other potential sources of bias
We judged one study to be at unclear risk of other potential sources
of bias (Casini 2006). The mean ages and duration of infertility
in the intervention and control group of women with submucous
fibroids were not reported; we failed to obtain these data from
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the study authors given that we were unsuccessful in contacting
them. It is unclear whether this might have caused imbalance in
the baseline characteristics between the comparison groups in this
randomised trial (Casini 2006). Moreover it is unclear whether
hysteroscopy had been performed in all participants to confirm
the position of the ultrasonically detected fibroids.
We judged the second study (Pérez-Medina 2005) to be at low risk
of other potential sources of bias since there was no evidence of
baseline imbalance in the patient characteristics between the two
comparison groups.
Publication bias could not be formally assessed due to the very
limited number of studies included in this Cochrane review.
Effects of interventions
See: Summary of findings for the main comparison Operative
hysteroscopy compared with control for unexplained subfertility
associated with suspected major uterine cavity abnormalities;
Summary of findings 2 Operative hysteroscopy compared with
control for suspected major uterine cavity abnormalities prior to
medically assisted reproduction
1. Operative hysteroscopy versus control in women
with otherwise unexplained subfertility and suspected
major uterine cavity abnormalities
Endometrial polyps
No studies were retrieved.
Submucous fibroids
We retrieved only one study comparing hysteroscopic myomec-
tomy versus regular fertility-oriented intercourse in women with
unexplained subfertility and submucous fibroids only or combined
with intramural fibroids (Casini 2006).
Primary outcomes
1.1. Live birth
There were no data for this primary outcome.
1.2. Adverse events: hysteroscopy complications
There were no data for this primary outcome.
Secondary outcomes
1.3. Clinical pregnancy
In women with otherwise unexplained subfertility for at least one
year and one submucous fibroid of diameter ≤ 40 mm, an im-
portant benefit with the removal of the fibroid by hysteroscopy
compared to regular fertility-oriented intercourse cannot be ruled
out for the secondary outcome of clinical pregnancy: there is no
conclusive evidence for statistically significant differences between
both comparison groups (odds ratio (OR) 2.44, 95% confidence
interval (CI) 0.97 to 6.17, P = 0.06, one randomised controlled
trial (RCT), 94 women) (Analysis 1.1; Figure 4).
Figure 4. Forest plot of comparison: 1 Hysteroscopic myomectomy vs regular fertility-oriented intercourse
in women with unexplained subfertility and submucous fibroids.Outcome: 1.1 Clinical pregnancy per woman
randomised.
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We pre-specified in the protocol (Bosteels 2011) that a minimally
important clinical difference (MICD) of 5% for the live birth
rate would be considered as being relevant for the benefits of the
intervention. The data for the one secondary outcome studied
indicate a clinically important difference of 18% (95% CI 0% to
37%, P = 0.05) between the two comparison groups. This is a post
hoc analysis.
1.4. Adverse events: miscarriage
There is no evidence for an effect of the hysteroscopic removal of
one submucous fibroid of diameter≤ 40 mm in subfertile women
with otherwise unexplained subfertility compared to regular fer-
tility-oriented intercourse for the secondary outcome of miscar-
riage per clinical pregnancy (OR 0.58, 95% CI 0.12 to 2.85, P =
0.50, one RCT, 30 clinical pregnancies in 94 women) (Analysis
1.2; Figure 5).
Figure 5. Forest plot of comparison: 1 Hysteroscopic myomectomy vs regular fertility-oriented intercourse
in women with unexplained subfertility and submucous fibroids. Outcome: 1.2 Miscarriage per clinical
pregnancy.
Subgroup analyses
No subgroup analyses across studies could be done to assess any
overestimation of treatment effect or reporting bias, due to the
limited number of studies.
One pre-specified subgroup analysis within the trial was done for
the two secondary outcomes of clinical pregnancy and miscarriage
according to whether submucous fibroids only or mixed submu-
cous-intramural fibroids were considered. There is no conclusive
evidence for statistically significant differences between both com-
parison groups for the secondary outcome clinical pregnancy in
the ’submucous only’ subgroup (OR 2.04, 95% CI 0.62 to 6.66,
P = 0.24, one RCT, 52 women), or the ’mixed submucous-intra-
mural’ subgroup (OR 3.24, 95% CI 0.72 to 14.57, P = 0.13, one
RCT, 42 women); the tests for subgroup differences demonstrated
no statistical heterogeneity beyond chance (Chi² = 0.22, df = 1 (P
= 0.64), I² = 0%). There is no conclusive evidence for statistically
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significant differences between both comparison groups for the
secondary outcome miscarriage in the ’submucous only’ subgroup
(OR 0.63, 95% CI 0.09 to 4.40, P = 0.64, one RCT, 19 clinical
pregnancies in 52 women) or the ’mixed submucous-intramural’
subgroup (OR 0.50, 95% CI 0.03 to 7.99, P = 0.62, one RCT,
11 clinical pregnancies in 42 women); the tests for subgroup dif-
ferences demonstrated no statistical heterogeneity beyond chance
(Chi² = 0.02, df = 1 (P = 0.90), I² = 0%).
Uterine septum
No studies were retrieved.
Intrauterine adhesions
No studies were retrieved.
2. Operative hysteroscopy versus control in women
undergoing medically assisted reproduction (MAR)
with suspected major uterine cavity abnormalities
Endometrial polyps prior to intrauterine insemination (IUI)
We retrieved only one study comparing hysteroscopic removal of
polyps versus diagnostic hysteroscopy and polyp biopsy in women
with endometrial polyps undergoing gonadotropin treatment and
IUI (Pérez-Medina 2005).
Primary outcomes
2.1. Live birth
There were no data for this primary outcome.
2.2. Adverse events: hysteroscopy complications
There were no data for this primary outcome.
Secondary outcomes
2.3. Clinical pregnancy
The hysteroscopic removal of polyps with a mean size of 16 mm,
detected byDoppler ultrasonography inwomenwith unexplained,
male or female factor infertility for at least 24 months bound to
undergo IUI, increases the odds of clinical pregnancy compared to
diagnostic hysteroscopy and biopsy only (OR 4.41, 95% CI 2.45
to 7.96, P < 0.00001, one RCT, 204 women) (Analysis 2.1; Figure
6). The number needed to treat to benefit is 3 (95% CI 2 to 4).
These results are based on an ’available data’ analysis. The data for
the one secondary outcome studied indicate a clinically important
difference of 35% (95% CI 22% to 48%, P < 0.00001) between
the two comparison groups favouring hysteroscopic polypectomy.
There is evidence of a clinically important increase of the clinical
pregnancy rate favouring hysteroscopic polypectomy compared
to diagnostic hysteroscopy and polyp biopsy. This is a post hoc
analysis, which was not pre-specified by the authors of the primary
study.
Figure 6. Forest plot of comparison: 2 Hysteroscopic removal of polyps vs diagnostic hysteroscopy and
biopsy only prior to IUI. Outcome: 2.1 Clinical pregnancy per woman randomised.
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2.4. Adverse events: miscarriage
There were no data for this secondary outcome.
Subgroup analyses
Although no subgroup analyses across studies were done to assess
any overestimation of treatment effect or reporting bias given the
limited number of studies, we did two subgroup analyses within
the included study.
A first pre-specified subgroup analysis studied the effect of
polyp size on the secondary outcome of clinical pregnancy. On
histopathological examination themean size of the polyps removed
was 16 mm (range 3 to 24 mm). In the primary study the effect
of the polyp size on the clinical pregnancy rate was studied in the
intervention group. The data were analysed based on the size of
the removed polyps, subdivided into four groups based in their
quartiles (< 5 mm, 5 to 10 mm, 11 to 20 mm and > 20 mm); the
differences between these four subgroups within this study were
not statistically significant (P = 0.32) (Table 1). There is no ev-
idence of an effect of the polyp size on the outcome of clinical
pregnancy, but these results should be interpreted carefully given
the limited numbers in only one included study. There were no
data on the estimated size of the polyps in the control group.
The second subgroup analysis studied the effect of the timingof the
IUI treatment after hysteroscopy on the secondary outcome clin-
ical pregnancy. About 29% of women in the polypectomy group,
compared to 3% in the diagnostic hysteroscopy group became
pregnant in the three-month period after the hysteroscopy before
the treatment with gonadotropin and IUI was started; this was cal-
culated from the Kaplan-Meier survival analysis in the published
report of the primary study (Pérez-Medina 2005). Hysteroscopic
polypectomy increases the odds of clinical pregnancy compared
to diagnostic hysteroscopy and polyp biopsy in women waiting to
be treated with gonadotropin and IUI (OR 13, 95% CI 3.9 to 46,
P < 0.0001, one study, 204 women, available data analysis). The
number needed to treat to benefit after hysteroscopic polypectomy
while waiting for further treatment with gonadotropin and IUI is
4 (95% CI 3 to 6). In women who started gonadotropin and IUI
treatment the pregnancy rates per woman were 49% and 26% in
the intervention and control group respectively, calculated from
data in the published report of the primary study (Pérez-Medina
2005). Hysteroscopic polypectomy increases the odds of clinical
pregnancy in women who started from three months after the sur-
gical procedure with gonadotropin and IUI treatment (OR 2.7,
95% CI 1.4 to 5.1, P = 0.003, one RCT, 172 women, available
data analysis). The number needed to treat to benefit when treated
with gonadotropin and IUI after a prior hysteroscopic polypec-
tomy is 4 (95% CI 3 to 12). We judged this to be an honest and
sensible post hoc analysis. Quoting from the primary study pub-
lished report “A second important conclusion in our study is that
pregnancies after polypectomy are frequently obtained spontaneously
while waiting for the treatment, suggesting a strong cause-effect of the
polyp in the implantation process. This led us to defer the first IUI
to three menstrual cycles after the polypectomy is performed. Longer
series are needed to verify these results”.
Sensitivity analyses
A sensitivity analysis comparing an intention-to-treat analysis as-
suming that clinical pregnancies would not have occurred in par-
ticipants with missing data, rather than an ’available data’ analy-
sis, did not affect the statistical significance of the main analysis
for the secondary outcome ’clinical pregnancy’ (OR 4.0, 95% CI
2.3 to 7.2, P < 0.00001, one RCT, 215 women randomised). No
other imputation strategies for dealing with the missing data were
assumed given the limited number of studies.
Endometrial polyps prior to in vitro fertilisation (IVF) or
intracytoplasmic sperm injection (ICSI)
No studies were retrieved.
Submucous fibroids prior to IUI, IVF or ICSI
No studies were retrieved.
Uterine septum prior to IUI, IVF or ICSI
No studies were retrieved.
Intrauterine adhesions prior to IUI, IVF or ICSI
No studies were retrieved.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Operative hysteroscopy compared with control for suspected major uterine cavity abnormalities prior to medically assisted reproduction
Patient or population: subfertile women with endometrial polyps diagnosed by ultrasonography prior to treatment with gonadotropin and intrauterine insemination
Settings: infertility unit of a university tertiary hospital in the Spanish capital Madrid
Intervention: hysteroscopic polypectomy using a 5.5 mm continuous flow office hysteroscope with a 1.5 mm scissors and forceps
Comparison: diagnostic hysteroscopy using a 5.5 mm continuous flow office hysteroscope and polyp biopsy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Polypectomy
Live birth No data were reported for this primary outcome.
Hysteroscopy complica-
tions
No data were reported for this primary outcome.
Clinical pregnancy
ultrasound1
4IUIcycles
Low-risk population2 OR 4.41
(2.45 to 7.96)
204
(1 study)
⊕⊕⊕©
moderate5
250 per 1000 595 per 1000
(450 to 726)
Medium-risk population3
366 per 1000 718 per 1000
(586 to 821)
High-risk population4
528 per 1000 831 per 1000
(733 to 899)
Miscarriage No data were reported for this secondary outcome.
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*The basis for the assumed risk in the low-, medium- or high-risk populations is the control group risk of three studies provided in the footnotes below. The corresponding risk (and its 95%
confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Clinical pregnancy was defined by the presence of at least one gestational sac on ultrasound.
2 Based on the clinical pregnancy rate per woman after 4 cycles gonadotropins and IUI for male factor subfertility based on data from
Bensdorp 2007.
3 Based on the clinical pregnancy rate per woman after 4 cycles gonadotropins and IUI for unexplained subfertility based on data from
Veltman-Verhulst 2012.
4 Based on the clinical pregnancy rate per woman after 4 cycles gonadotropins and IUI for female factor subfertility based on data from
Spiessens 2003.
5 There was high risk for selective outcome reporting.
2
4
H
y
ste
ro
sc
o
p
y
fo
r
tre
a
tin
g
su
b
fe
rtility
a
sso
c
ia
te
d
w
ith
su
sp
e
c
te
d
m
a
jo
r
u
te
rin
e
c
a
v
ity
a
b
n
o
rm
a
litie
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
D I S C U S S I O N
Summary of main results
This systematic review aimed to investigate whether the hystero-
scopic treatment of suspected major uterine cavity abnormalities
made a difference to the main outcomes of live birth or pregnancy
and the adverse events - hysteroscopy complications and miscar-
riage - in subfertile women with otherwise unexplained subfertil-
ity or before intrauterine insemination (IUI), in vitro fertilisation
(IVF) or intracytoplasmic sperm injection (ICSI). We searched
for studies on two randomised comparisons to study the effec-
tiveness of operative hysteroscopy in the treatment of subfertility
associated with major uterine cavity abnormalities. The first ma-
jor randomised comparison is operative hysteroscopy versus con-
trol in women with otherwise unexplained subfertility and sus-
pectedmajor uterine cavity abnormalities - stratified into endome-
trial polyps, submucous fibroids, intrauterine adhesions or septate
uterus - diagnosed by ultrasonography (US), saline infusion/gel
instillation sonography (SIS,GIS), hysterosalpingography (HSG),
diagnostic hysteroscopy or any combination of these methods.
The second randomised comparison is operative hysteroscopy ver-
sus control in women undergoing medically assisted reproduction
(MAR) - stratified into IUI, IVF or ICSI - with suspected major
uterine cavity abnormalities - stratified into endometrial polyps,
submucous fibroids, intrauterine adhesions or septate uterus - di-
agnosed by US, SIS, GIS, HSG, diagnostic hysteroscopy or any
combination of these methods.
We critically appraised one single trial (Casini 2006) comparing
hysteroscopic removal of one submucous fibroid with a diameter
≤ 40 mm in women aged≤ 35 years with otherwise unexplained
subfertility versus regular fertility-oriented intercourse for a pe-
riod of 12 months. An important benefit with the removal of sub-
mucous fibroids by hysteroscopy in women with otherwise unex-
plained subfertility compared to expectant management cannot
be excluded for the secondary outcome of clinical pregnancy. The
lack of conclusive evidence for statistically significant differences
between both comparison groups may be due to a type II error:
we calculated that a sample size of 91 participants is needed to
detect a difference of 19% for the outcome of clinical pregnancy
between both comparison groups with a statistical power of 80%
at a confidence level of 95% (α = 0.05 and ß = 0.20). In other
words, a study population of at least 182 participants is needed to
detect any statistically significant difference if present; compared
to only 94 women in the single included study (Casini 2006). We
did not retrieve any trials on operative hysteroscopy versus control
in women with otherwise unexplained subfertility and suspected
endometrial polyps, intrauterine adhesions or septate uterus.
We found only one single trial (Pérez-Medina 2005) for the second
comparison of randomised interventions. According to the results
of the randomised comparison ’hysteroscopic polypectomy ver-
sus diagnostic hysteroscopy comparison in subfertile women with
suspected endometrial polyps bound to undergo IUI’, there is ev-
idence for a clinically relevant and statistically significant increase
in the odds of clinical pregnancy favouring the hysteroscopic re-
moval of polyps with a mean size of 16 mm (range 3 to 24 mm).
A sensitivity analysis on the choice to use an intention-to-treat
analysis by making the imputation that clinical pregnancies would
not have occurred in participants with missing data rather than
an ’available data’ analysis did not demonstrate an impact on the
overall results. There were no data for the primary outcomes of live
birth and hysteroscopy complications and the secondary outcome
of miscarriage. The increase in clinical pregnancies after hystero-
scopic polypectomy might be mainly due to a higher proportion
of spontaneous conceptions before starting IUI and to a lesser, but
still clinically relevant, extent to a higher odds of conceiving after
starting gonadotropin treatment and IUI. The results of this sen-
sible post hoc subgroup analysis should be interpreted with cau-
tion; at present no definitive conclusions can be made concerning
the timing of the hysteroscopic intervention in relationship to the
subsequent IUI treatment based on one single moderate quality
trial. There is no evidence for an effect of the size of the polyps
on the outcome clinical pregnancy, but given the limited numbers
this subgroup analysis should equally be interpreted with caution.
No data on the polyp size were available from the control group:
given the arbitrary distinction between biopsying or removing a
very small polyp, the probability that the true treatment effect of
hysteroscopic polypectomy might even have been underestimated
can neither be proven nor ruled out.
Due to the lack of studies no formal assessment of publication bias
was done.
Overall completeness and applicability of
evidence
Evidence on the effectiveness of treating suspected major uterine
cavity abnormalities by operative hysteroscopy compared to a con-
trol intervention in women with otherwise unexplained subfertil-
ity is very limited. We found no trials on the hysteroscopic treat-
ment of endometrial polyps, intrauterine adhesions or septa com-
pared to a control intervention in women with otherwise unex-
plained subfertility. The only included study in this category fails
to report on the primary outcomes for this review. Evidence on
the effectiveness of operative hysteroscopy compared to control in
subfertile women with associated major uterine cavity abnormal-
ities prior to medically assisted reproduction is incomplete since
data have been found only for subfertile women with suspected
endometrial polyps prior to IUI. No data were retrieved on the
effectiveness of operative hysteroscopy versus control in subfertile
women with other suspected major cavity abnormalities such as
submucous fibroids, intrauterine adhesions or septa prior to IUI or
other techniques such as IVF or ICSI for all outcomes. Moreover,
for the randomised comparison hysteroscopic polypectomy ver-
sus diagnostic hysteroscopy prior to IUI, no data are available for
the primary outcomes. The evidence retrieved is by consequence
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insufficient to address all the objectives of the present Cochrane
review.
The lack of statistical significance of the differences between the
comparison groups in the trial of hysteroscopic myomectomy in
women with submucous fibroids and otherwise unexplained sub-
fertility does not exclude the possibility of a clinically relevant
benefit with the hysteroscopic removal of fibroids. It is generally
accepted that submucous fibroids are very likely to interfere with
normal fertility (Pritts 2001; Pritts 2009). In everyday practice
most skilled hysteroscopic surgeons will counsel women with sub-
mucous fibroids associated with otherwise unexplained subfertil-
ity or bound to be treated with IUI, IVF or ICSI to have the sub-
mucous fibroids removed before further expectant management
or MAR; besides offering participation in a pragmatic RCT on
this topic there just seems no other sound clinical alternative.
Although the results of the trial on hysteroscopic polypectomy
(Pérez-Medina 2005) are relevant for everyday practice, one-third
of the randomised women treated by IUI suffered from an ovu-
latory disorder other than anovulation. In everyday clinical prac-
tice ovulatory disorder is by itself not an indication for IUI as
opposed to male factor (Bensdorp 2007) and unexplained subfer-
tility (Veltman-Verhulst 2012). We have considered doing a sen-
sitivity analysis to study if the inclusion and exclusion of women
with ovulatory disorders could have influenced the magnitude of
the treatment effect but failed to obtain the data from the study
authors.
Quality of the evidence
See Table 2 and Table 3. See also Summary of findings for the
main comparison and Summary of findings 2.
The present review included only two trials; neither reported the
primary outcomes live birth or hysteroscopy complications.
Using the GRADE tool as implemented in GRADE profiler, we
graded the evidence of the first trial on hysteroscopic myomec-
tomy (Casini 2006) as ’very low’. It is a small study with few
events. The keymethodological limitations of this study are many:
there is uncertainty about allocation concealment and it is unclear
whether there was imbalance in the baseline characteristics of the
study groups. There is a high risk of selective outcome reporting.
Moreover, the results are imprecise given the wide confidence in-
tervals of the point estimate of the treatment effect. The effect
of imprecision is to make the observed association closer to the
null value than is the true association. The pre-planned subgroup
analysis in terms of removal of submucous fibroids only or mixed-
submucous intramural fibroids showed no evidence for an effect
favouring the removal of fibroids compared to regular fertility-
oriented intercourse; the absence of a treatment effect is consistent
with the findings for the removal of submucous fibroids ’overall’.
Although the interpretation of the statistical analysis of subgroups
is problematic, there is no evidence of serious inconsistency.
The evidence of the second trial on hysteroscopic polypectomy
(Pérez-Medina 2005) was graded as ’moderate’: there was a high
risk of selective outcome reporting (see Assessment of risk of bias
in included studies). This study had adequate statistical power to
detect a difference between the comparison groups. There was no
evidence for a dose-response relationship between the size of the
polyps and the treatment effect of the hysteroscopic polypectomy
according to the only pre-specified subgroup analysis. These find-
ings should nevertheless be interpretedwith great caution. Accord-
ing to a sensible post hoc analysis the treatment effect of hystero-
scopic polypectomy is consistent among the subgroups of women
waiting to be treated after hysteroscopy with gonadotropins and
IUI and those who started gonadotropin treatment and IUI. Nev-
ertheless, the use of post hoc analyses looking at subgroups af-
ter the trial has been conducted is open to potential problems of
multiple comparisons and comparisons between non-randomised
groups.
Potential biases in the review process
There is an earlier published version of this review (Bosteels 2010).
Given our prior knowledge of potentially eligible studies for this
clinical research topic, there might have been some potential for
detection bias. We have carried out a comprehensive literature
search using a search strategy which was more extensive than the
one used in the earlier published systematic review. This enabled
us to identify a far greater number of randomised studies on hys-
teroscopic surgery in subfertile women, many of which do not
address the particular research questions pre-specified in the pro-
tocol (see Characteristics of excluded studies).
Agreements and disagreements with other
studies or reviews
We briefly discuss the findings of two systematic reviews on fi-
broids and subfertility (Pritts 2001; Pritts 2009). We refer to the
data in the most recent review since the MOOSE (Meta-analysis
of Observational Studies in Epidemiology) guidelines for system-
atic reviews of observational studies were followed (Pritts 2009).
Two types of observational studies were identified: those control-
ling with women having fibroids in situ, and those using subfertile
women without fibroids as control participants. If fibroid removal
is beneficial, women treated by myomectomy would be expected
to have higher pregnancy rates and lower miscarriage rates than
those with fibroids in situ. In women with submucous fibroids,
the clinical pregnancy rates were higher in themyomectomy group
(risk ratio (RR) 2.0, 95% CI 1.1 to 3.8, two studies, P = 0.028).
The differences between both groups for the ongoing pregnancy/
live birth rates failed to reach statistical significance (RR 2.6, 95%
CI 0.92 to 7.6, one study, P > 0.05). There was no evidence for
differences in themiscarriage rates between both groups (RR 0.77,
95%CI 0.36 to 1.7, one study, P > 0.05). When the control group
consists of subfertile womenwithout fibroids,myomectomymight
be expected (if beneficial) to normalise the rates compared with
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controls. For women with submucous fibroids treated by hystero-
scopic myomectomy, there was no evidence for statistically sig-
nificant differences in clinical pregnancy rates (RR 1.5, 95% CI
1.0 to 2.4, two studies, P > 0.05), ongoing pregnancy/live birth
rates (RR 1.1, 95% CI 1.0 to 1.3, three studies, P > 0.05) and
miscarriage rates (RR 1.2, 95% CI 0.47 to 3.2, two studies, P >
0.05) compared to subfertile women without submucous fibroids.
Meta-regression demonstrated that the study quality scores did
not significantly affect the observed effect in the meta-analyses.
Furthermore, sensitivity analyses comparing the use of the studies
with the highest study quality did not affect the statistical signifi-
cance of the main results compared to the use of all the retrieved
studies, irrespective of the study quality. There was no evidence of
publication bias in the systematic review of the literature done by
this research group. The authors concluded that the fertility out-
comes are decreased in women with submucosal fibroids, and re-
moval is likely to benefit the reproductive outcome. These findings
are not in accordance with the findings of a Cochrane review on
the surgical treatment of fibroids for subfertility (Metwally 2012):
according to these authors a large benefit favouring hysteroscopic
myomectomy cannot be excluded, which is consistent with the
findings of the present Cochrane review.
The results of the trial on the effectiveness of hysteroscopic
polypectomy prior to IUI are consistent with the findings of two
recently published observational studies. The first study planned
to evaluate the effect of the presence of endometrial polyps onpreg-
nancy rates and how polypectomy could affect pregnancy rates in
171 women scheduled for IUI (Kalampokas 2012). The presence
of an endometrial polypwas diagnosed during the infertility evalu-
ation. The study group consisted of 86 women who, following the
diagnosis of endometrial polyp, agreed to have the polyps removed
hysteroscopically prior to the IUI. The control group consisted of
85 women who, despite the fact that the presence of an endome-
trial polyp was previously diagnosed and its removal suggested,
elected not to have the polyp removed. There was a statistically sig-
nificant difference in cumulative pregnancy rates between the two
groups, favouring hysteroscopic polypectomy. The authors con-
cluded that hysteroscopic polypectomy appears to improve fertil-
ity in women with otherwise unexplained infertility. The second
study, a prospective clinical controlled study including120women
with endometrial polyps, aimed to study whether polypectomy
before intrauterine insemination achieved better pregnancy out-
comes than no intervention (Shohayeb 2011). All patients were
scheduled to receive four cycles of IUI in both groups within 12
months duration. The first IUI cycle was planned after three men-
strual cycles in both groups. Cumulative pregnancy rate in both
groups after four IUI cycles was 23 (38.3%) in the study group
and 11 (18.3%) in the control group (P = 0.015). The authors
concluded that persistent endometrial polyps are likely to impair
reproductive performance and that hysteroscopic polypectomy be-
fore IUI could be considered as an effective intervention. A sys-
tematic review (Lieng 2010b) included 11 studies in 935 subfer-
tile women with endometrial polyps: one randomised controlled
trial (Pérez-Medina 2005), three clinical controlled studies and
seven observational studies (three retrospective, one prospective
and three undetermined). Although there was no evidence for an
effect favouring hysteroscopic polypectomy on the IVF outcomes
according to two smaller non-randomised observational studies,
the limited evidence suggests a favourable outcome on pregnancy
rates in subfertile women with endometrial polyps. Due to the
clinical diversity formal meta-analysis was rightfully judged to
be inappropriate. The methodology for meta-analysis of observa-
tional studies proposed by The Cochrane Collaboration was not
followed (no formal appraisal of the risk of bias, no study of the
effect of confounders, no formal assessment of publication bias);
therefore, the authors’ conclusion should be interpreted with great
caution. Finally, in a recent Cochrane review (Jayaprakasan 2014),
the need for additional well-designed RCTs on the effectiveness of
hysteroscopic polypectomy for improving reproductive outcome
in subfertile women was stressed, which is in accordance with our
findings.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A large benefit with hysteroscopic myomectomy in women with
otherwise unexplained subfertility cannot be excluded. There was
no conclusive evidence for statistically significant differences in
clinical pregnancy rates between the comparison groups in the sin-
gle published randomised trial.The quality of the evidence pro-
vided by this small single-centre study was graded as very low.
There may be a benefit with hysteroscopic polypectomy for im-
proving the chance of conceiving in subfertile women with a sono-
graphic diagnosis of endometrial polyps prior to intrauterine in-
semination for unexplained, male or female factor infertility for at
least 24 months. We graded the quality of evidence provided by
this single study as moderate.
Implications for research
The evidence retrieved from the limited number of randomised
studies is insufficient to address all the objectives of the present
review.
More well-designed randomised controlled trials are needed to
assess whether the hysteroscopic removal of endometrial polyps,
submucous fibroids, septa or intrauterine adhesions is likely to
benefit women with otherwise unexplained subfertility associated
with these suspected uterine pathologies compared to a control in-
tervention. Equally, more clinical research is needed on the effec-
tiveness of treating endometrial polyps, submucous fibroids, septa
or intrauterine adhesions in subfertile women bound to undergo
IUI, IVF or ICSI.
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There are knowledge gaps concerning the effects of the number,
size or extent and the localisation of the major uterine cavity ab-
normalities on the main outcomes in women with otherwise un-
explained subfertility or prior to medically assisted reproduction.
Well-designed randomised studies are needed to assess the rela-
tionship between the timing of the hysteroscopic intervention and
subsequent IUI, IVF or ICSI treatment.
Future randomised studies should report on primary outcomes
such as live birth and adverse events such as miscarriage and hys-
teroscopic complications.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Casini 2006
Methods Parallel-group, randomised, controlled, single-centre trial
Power calculation not reported
Approved by the hospital’s ethics committee
No source of funding or conflict of interest reported
Participants Country: Italy
Setting: AGUNCO Obstetrics and Gynecology Centre, Rome
Population: women referred to the centre from January 1998 until April 2005 for fer-
tility problems were examined for inclusion in the study. All women underwent routine
examinations including the study of ovarian function (FSH, luteinising hormone, estra-
diol and progesterone concentrations); prolactin, free triiodothyronine, free thyroxine
and thyroid-stimulating hormone concentrations; post-coital test; TVUS; hysterosalp-
ingography; and analysis of the partner’s semen. The TVUS was performed in order to
diagnose the presence of uterine fibroids. After these examinations all patients who were
found to be affected by uterine fibroids excluding all other causes of infertility were asked
to participate in the study
Type of subfertility: all women had been suffering from infertility for at least 1 year
(range: 1 to 5 years); no further clarification on primary versus secondary subfertility
Mean age: the mean age in the patients with submucous fibroids alone was 31.4 ± 2.5
years; the mean age in the patients with mixed submucous-intramural fibroids was 32.2
± 2.5 years
N recruited = 193 women
N participants = 181 women
N participants with submucous fibroids only = 52 women
N participants with mixed submucous-intramural fibroids = 42 women
Inclusion criteria: age ≤ 35 years; infertility for at least 1 year; presence of one knot
and/or fibroid of diameter ≤ 40 mm and absence of other causes of infertility at the
performed examinations
Exclusion criteria: presence of 2 or more knots and/or fibroids of diameter > 40 mm;
body weight > 20% of normal weight; and use of medication containing oestrogens,
progestins or androgens within 8 weeks prior to the study
Duration of the study: 86 months; the study was conducted from January 1998 until
April 2005
Interventions Two interventions were compared:
• The intervention group was treated with hysteroscopic surgery to remove the
fibroids (n = 52)
• The control group was not treated (n = 42)
Patients were examined by TVUS 3 months after surgery for control
Patients who did not undergo surgery were asked to immediately start having regular
fertility-oriented intercourse (intercourse during the 6-day fertile interval ending on
the day of ovulation). Patients who underwent surgery were suggested to abstain from
having sexual intercourse for 3 months and then to start having regular fertility-oriented
intercourse
Patients were monitored for up to 12 months after study commencement
35Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Casini 2006 (Continued)
Outcomes A clinical pregnancy was defined by the visualisation of an embryo with cardiac activity
at 6 to 7 weeks of pregnancy
Miscarriage was classified as clinical loss of an intrauterine pregnancy between the 7th
and 12th weeks of gestation
Notes The authors state that the differences in pregnancy rates between the comparison groups
are statistically significant for the patients with submucous fibroids (P < 0.05), which is
in contrast with the calculation of the results in RevMan
The definition of knot is unclear: it could not be clarified since we failed to contact the
study authors
It is not clear whether a hysteroscopy was done in all women to confirm the exact position
of the ultrasonically detected fibroids
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subsequently, women of each group
were randomized into two subgroups, accord-
ing to a randomisation table”
Comment: low risk of selection bias related
to random sequence generation
Allocation concealment (selection bias) Unclear risk Method not stated: no further clarification
obtained from the study authors
Comment: unclear risk of selection bias re-
lated to allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method not stated: no further clarification
obtained from the study authors
Comment: unclear risk of performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not stated: no further clarification
obtained from the study authors
Comment: unclear risk of detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One hundred and ninety-three pa-
tients were diagnosed as affected by uterine
fibroid excluding all other causes of infertil-
ity and met the requirements of the inclusion
and exclusion criteria. Of these, 181 decided
to participate in the study. Among the 181
patients, 52 had submucosal fibroids (SM
group) while 45 had intramural fibroids (IM
group), 11 had subserosal fibroids (SS group),
42 had amix of submucosal-intramural (SM-
IM group) and 31 patients had a mix of in-
tramural-subserosal fibroids (IM-SS group)”.
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Casini 2006 (Continued)
Quote: “Out of 181women, 68 become preg-
nant”
Comment: low risk for attrition bias
Selective reporting (reporting bias) High risk The published report fails to include results
for the live birth rate, which is the primary
outcome of interest that would be expected
to have been reported for a trial on fertility
treatment conducted over a 7-year period
Other bias Unclear risk The mean ages and duration of infertility
in the intervention and control group of
womenwith submucous fibroids are not re-
ported. No further clarification by the au-
thors was obtained
It is unclear whether there might have been
imbalance in the baseline characteristics be-
tween the comparison groups
Failure to do a hysteroscopy in all women
to confirm the position of the ultrasonically
detected fibroids could have caused infor-
mation bias
Pérez-Medina 2005
Methods Parallel-group, randomised, controlled, single-centre trial
A power analysis was performed. To detect an expected difference in pregnancy rate
between the intervention and control group of 15% at a level of 0.05 with a power of
80%, a sample size of 200 women (i.e. 100 women per group) was required. From 2800
women attending the centre, 452 women fulfilling the inclusion criteria were selected;
215 women were randomised (107 women in the intervention group and 108 women in
the control group). Data on outcomes of 204 women were available for analysis (101 in
the intervention group and 103 in the control group). This study had therefore adequate
statistical power to detect a difference between the comparison groups if really present
Approved by the hospital’s ethics committee
No source of funding or conflict of interest reported
Participants Country: Spain
Setting: infertility unit of an university tertiary hospital in the Spanish capital Madrid
Population: women with unexplained, male or female factor infertility for at least 24
months bound to undergo intrauterine insemination with a sonographic diagnosis of
endometrial polyps
Unexplained infertility was diagnosed in patients with normal ovulatory cycles, semen
analysis, HSG and postcoital testing. Male factor infertility was diagnosed if 2 semen
analyses obtained at least 1 month apart were subnormal according to theWHO criteria.
Female factor infertility was diagnosed in patients with ovulatory dysfunction, cervical
factor or endometriosis
Type of subfertility: primary subfertility (correspondence with the study authors)
Mean age: treatment group = 30.8 years (26.7 to 34.9), control group = 30.9 years (26.
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Pérez-Medina 2005 (Continued)
5 to 35.3)
N recruited = 452 women
N randomised = 215 women
Inclusion criteria: women with at least 24 months of subfertility with a sonographic
diagnosis of endometrial polyps bound to undergo intrauterine insemination for unex-
plained, male or female factor infertility
Exclusion criteria: women > 39 years of age, anovulation, azoospermia, uncorrected tubal
disease or previous unsuccessful use of recombinant FSH
Duration of the study: 50 months; the study was conducted from January 2000 to
February 2004
Interventions One surgeon (the first author of the study TP-M) performed all hysteroscopic procedures
by intention in an outpatient office setting under local anaesthesia
Two interventions were compared:
• Hysteroscopic polypectomy using a 5.5 mm continuous flow office hysteroscope
with a 1.5 mm scissors and forceps (n = 107)
• Diagnostic hysteroscopy using a 5.5 mm continuous flow office hysteroscope and
polyp biopsy (n = 108)
Duration: women were scheduled to receive 4 cycles of IUI with subcutaneous injection
of recombinant FSH 50 IU daily from the third day, and the first IUI was planned for
3 cycles after hysteroscopy in both groups. 4 IUI cycles were attempted before finishing
the trial
Outcomes Primary: Quote: “We studied the crude pregnancy rate in both groups”
Comment: clinical pregnancy; crude pregnancy was defined by the study authors as
follows: “the presence of a gestational sac on ultrasound” (correspondence with the study
authors)
Secondary: time-to-pregnancy and influence of the size of the endometrial polyps on the
pregnancy rate
Notes 1. Quote: “Patients underwent a complete infertility evaluation that included TVUS in the
early proliferative phase, basal body temperature recording to assess ovulation, postcoital test
(PCT), HSG, semen analysis and, in some patients, diagnostic laparoscopy”
Comment: according to correspondence with the first author, the aim of the laparoscopy
was exclusively diagnostic in the evaluation of cases of unexplained infertility of un-
known origin. If tubal pathology was detected by laparoscopy, the patient was excluded
from randomisation. The numbers of women undergoing a laparoscopy were balanced
between the 2 comparison groups
2. In this study IUI was performed for various indications: male factor (21%), cervical
factor (11%), endometriosis (11%), or unexplained subfertility (49%) and ovulation
disorder (33%). Anovulation is reported in themethods section as an exclusion criterion.
The study authors defined ovulation disorder as follows: Quote: “A combination of irreg-
ular menstrual cycles with multicystic ovaries on TVUS and basal gonadotrophin measure-
ments within the normal range” (correspondence with the first study author). Comment:
In everyday clinical practice ovulation disorder is not an indication for IUI by itself
3. Data on the number or the localisation of the polyps could not be retrieved since the
first author no longer works in the university hospital
4. Data on the size of the polyps in the control group could not be obtained for similar
reasons as footnote 3
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Pérez-Medina 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised to one of
the two groups with use of an opaque envelope
technique, with assignment determined by a
computerized random number table”
Quote: “Subjects were randomised into one
of two groups in a 1:1 ratio using a restricted
randomisation”
Comment: probably done, but using sim-
ple randomisation, with an equal alloca-
tion ratio, by referring to a table of random
numbers generated by a computer
Allocation concealment (selection bias) Low risk Quote: “Patients were randomised to one of
the two groups with use of an opaque envelope
technique, with assignment determined by a
computerized random number table”.
Comment: sequentially
numbered, opaque, sealed envelopes were
used according to correspondence with the
first author; probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method not stated: no further clarification
obtained from the study authors
Comment: unclear risk of performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not stated: no further clarification
obtained from the study authors
Comment: unclear risk of detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “11 patients were lost from the study,
6 in the study group (3 lost to follow-up, 2
pathologic reports of submucosal myoma and
1 in whom the polyp was not confirmed) and
5 in the control group (1 lost to follow-up, 2
in whom the polyp was not confirmed and 2
pathologic reports of myoma)”
Comment: missing outcome data are bal-
anced in numbers across the comparison
groups, with similar reasons for missing
data across groups
Selective reporting (reporting bias) High risk Although the published report includes re-
sults on all the outcomes specified in the
methods section, it nevertheless fails to in-
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Pérez-Medina 2005 (Continued)
clude results for the live birth rate, which
is the primary outcome of interest that
would be expected to have been reported
for a trial on fertility treatment conducted
over a 4-year period. Data on the out-
comes live birth and miscarriage were not
available since most the majority of ran-
domised women were referred by gynaecol-
ogists from outside the tertiary university
hospital and were referred back when preg-
nant for further follow-up by the referring
gynaecologist.No clarification could be ob-
tained for the lack of data on hysteroscopic
complications
Other bias Low risk No evidence for imbalance in the baseline
characteristics
FSH: follicle-stimulating hormone
HSG: hysterosalpingography
IU: international units
IUI: intrauterine insemination
TVUS: transvaginal ultrasound
WHO: World Health Organization
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abu Rafea 2013 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing intrauterine balloon stenting versus no stenting following hys-
teroscopic treatment for septate uterus
Acunzo 2003 Not addressing the research questions described in the protocol
Parallel-group randomised trial studying the efficacy of hyaluronic acid gel in preventing the development of
intrauterine adhesions following hysteroscopic adhesiolysis. Mixed population of women with intrauterine
adhesions, presenting with subfertility or other gynaecological complaints. Primary outcome: adhesion
scores
Aghahosseini 2012 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing hysteroscopy prior to a subsequent IVF attempt versus immediate
IVF without prior hysteroscopy conducted in patients with 2 or more failed IVF cycles with unsuspected
or no uterine cavity abnormalities. Main outcomes: biochemical pregnancy, clinical pregnancy and delivery
rates
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(Continued)
Amer 2010 Not addressing the research questions described in the protocol
Parallel-group randomised trial in subfertile women comparing the application of amnion graft, either
fresh or dried to an intrauterine balloon versus the application of an intrauterine balloon without amnion
graft as an adjunctive procedure after the hysteroscopic lysis of severe intrauterine adhesions, diagnosed at
office hysteroscopy in women with infertility with or without menstrual disorders as the primary symptom.
Outcomes assessed were improvement in adhesion grade, improvement in menstruation, increased uterine
length at sounding, complications and reproductive outcome
Colacurci 2007 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing two different surgical techniques for metroplasty: operative
hysteroscopy using the resectoscope with a unipolar knife versus the Versapoint device. Mixed population
of women with septate uterus and a history of recurrent miscarriage or primary subfertility. Outcomes
assessed were operative parameters, complications, need for a second intervention and reproductive outcome
parameters
Darwish 2008 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing extended sectioning by resectoscopy versus sequential cold knife
excision for treating a complete utero-cervicovaginal septum in amixed population of women suffering from
infertility or pregnancy loss.Main outcomemeasures: operating time, perioperative bleeding, complications,
reproductive outcome, and patient and husband satisfaction
De Angelis 2010 Study on the effectiveness of hysteroscopic metroplasty for small septate uterus in women with repeated
IVF implantation failure. Although denoted by the authors as the first prospective randomised controlled
study on this subject, the trial did not use a valid random sequence generation
Quote: “These patients, once informed about the situation, were randomly allocated, depending on their
personal decision ...”
De Iaco 2003 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing the application of hyaluronan derivative gel (Hyalobarrier®
gel) after hysteroscopic surgery versus surgical treatment alone in women aged 18 to 65 years, suffering
from other gynaecological conditions than subfertility. Primary outcome: adhesion score at second look
hysteroscopy
Demirol 2004 Not addressing the research questions described in the protocol
Parallel-group randomised comparison between office hysteroscopy prior to a subsequent IVF attempt or
immediate IVF without prior office hysteroscopy conducted in patients with 2 or more failed IVF cycles
with unsuspected or no uterine cavity abnormalities. Outcome measures: number of oocytes retrieved,
fertilisation rate, number of embryos transferred, first trimester miscarriage and clinical pregnancy rates
Di Spiezio Sardo 2011 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing the use of Intercoat® absorbable adhesion barrier gel versus no
adhesion barrier after hysteroscopic synechiolysis in a mixed population of women suffering from infertility
or other gynaecological conditions. Primary outcome: incidence of de novo intrauterine adhesions, adhesion
scores, patency of the internal uterine ostium
El-Nashar 2011 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing diagnostic hysteroscopy with directed biopsy and/or hystero-
scopic treatment of unsuspected uterine cavity abnormalities versus no hysteroscopy in women with primary
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infertility treated with ICSI. Primary outcome: clinical pregnancy
El-Toukhy 2009 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing hysteroscopy versus no hysteroscopy in women with recurrent
implantation failure with IVF.Status: completed
Elsetohy 2015 Not addressing the research questions described in the protocol
Parallel-group randomised trial aimed at assessing the role of using the office hysteroscopy as a routine
investigation in improving ICSI pregnancy rates in two groups of infertile women with no abnormality
detected on transvaginal ultrasonographic examination
Fatemi 2007 Not addressing the PICO research question of this Cochrane review
Gao 2013 Observational non-randomised study on the effectiveness of hysteroscopy in women with repeated implan-
tation failure
Guida 2004 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing hysteroscopic surgery for the removal of polyps, fibroids or septa
followed by the application of auto-cross linked hyaluronic acid gel versus hysteroscopic surgery without
the adhesion barrier in a mixed population of women with subfertility and other gynaecological symptoms
associated with endometrial polyps, submucous fibroids or septa. Main outcomes: rates of adhesion forma-
tion and adhesion scores
Lieng 2010a Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing transcervical resection by hysteroscopy of endometrial polyps
suspected onTVUS and SIS versus observation for 6months. The study population included premenopausal
women with bleeding problems associated with endometrial polyps. The aim of the trial was to study the
clinical effectiveness of transcervical resection of endometrial polyps for the outcome periodic blood loss.
Women wishing to become pregnant were excluded from the trial. Primary outcome: periodic blood loss
measured by the Pictorial Blood Assessment Chart
Lin 2014 Not addressing the research questions described in the protocol
Randomised trial comparing the efficacy of intrauterine balloon and intrauterine contraceptive device in
the prevention of adhesion reformation following hysteroscopic adhesiolysis
Mohammed 2014 Comparative non-randomised study on the value of hysteroscopy prior to IVF/ICSI
Muzii 2007 Not addressing the research questions described in the protocol
Parallel-group randomised trial in women aged 18 to 75 years comparing operative hysteroscopy using the
monopolar resectoscope versus hysteroscopic bipolar electrode excision for the treatment of endometrial
polyps. Outcomes: operating times, difficulty of the operation, surgeon satisfaction with the procedure,
complications, postoperative pain and patient satisfaction
Pabuccu 2008 Quasi-randomised trial comparing early second look office hysteroscopic adhesiolysis after hysteroscopic
adhesiolysis and IUD insertion versus no early second look operative hysteroscopy in subfertile women with
intrauterine adhesions. The method of sequence generation is based on alternation: women were allocated
to the intervention or control groups based on their study entry
Main outcomes: pregnancy and live birth rate.
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Pansky 2009 Not addressing the research questions described in the protocol
Parallel-group randomised trial studying the effectiveness of an anti-adhesion barrier gel in women treated
by operative hysteroscopy for retained products of conception. Status:completed
Parsanezhad 2006 Not addressing the research questions described in the protocol
Parallel-group randomised trial in a mixed study population of women with a history of pregnancy wastage
or infertility and an associated complete uterine septum comparing metroplasty with complete section of the
cervical septum versus metroplasty with preservation of the cervical septum. Outcome measures: operating
time, distending media deficit, total distending media used, intraoperative bleeding, complications and
reproductive outcome
Rama Raju 2006 Not addressing the research questions described in the protocol
Parallel-group randomised trial conducted in patients with 2 or more failed IVF cycles with unsuspected
or no uterine cavity abnormalities comparing office hysteroscopy prior to a subsequent IVF attempt or
immediate IVF without prior hysteroscopy. Outcomes: number of oocytes retrieved, fertilisation rate,
number of embryos transferred and clinical pregnancy rates
Shawki 2010 Not addressing the research questions described in the protocol
Parallel-group randomised trial conducted to determine the incidence of unsuspected uterine cavity abnor-
malities detected by office hysteroscopy in patients before ICSI treatment compared to ICSI without prior
hysteroscopy. Main outcomes were the incidence of unsuspected uterine abnormalities and implantation
and clinical pregnancy rates
Shokeir 2010 Published report describing a parallel-group randomised trial comparing hysteroscopic myomectomy versus
diagnostic hysteroscopy andbiopsy inwomenwith otherwise unexplainedprimary infertility and submucous
fibroids. Primary outcome: clinical pregnancy rates
Quote from Fertility and Sterility searched on 16 January 2012: “This article has been retracted at the request
of the editor as it duplicates parts of a paper that had already appeared in Hum. Reprod., 20 (2005) 1632-1635,
DOI:10.1093/humrep/deh822”.
Tonguc 2008 Not addressing the research questions described in the protocol
Parallel-group randomised comparing hysteroscopic lysis of intrauterine adhesions with or without adjunc-
tive therapy (cyclical hormone replacement therapy alone or intrauterine device alone or both co-treatments
combined) after hysteroscopic metroplasty in a mixed population of women with subfertility and/or recur-
rent miscarriage. Main outcomes: incidence of de novo adhesion formation and ongoing pregnancy rate
Trnini -Pjevi 2011 Clinical controlled trial on the effectiveness of hysteroscopy prior to IVF; no random sequence generation
van Dongen 2008 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing the hysteroscopic removal of polyps or fibroids by conventional
hysteroscopy using a resectoscope versus hysteroscopic morcellation in a mixed population of women
suffering from infertility or other gynaecological conditions. Outcomemeasures: mean number of insertions
into the uterine cavity and mean operating time
Vercellini 1993 Not addressing the research questions described in the protocol
Parallel-group randomised comparing metroplasty using the resectoscope versus micro scissors for treating
uterine septum in women with repeated miscarriage. Outcome measures: mean operating time, mean
amount of distension medium used and complications
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Youssef 2013 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing 2 different surgical techniques for metroplasty: resectoscopy with
monopolar knife versus small-diameter hysteroscopy fitted with a 5 Fr reusable bipolar electrode.Outcomes
measures included pregnancy, miscarriage and live birth rates
ICSI: intracytoplasmic sperm injection
IUD: intrauterine device
IVF: in vitro fertilisation
PICO: Participants, Interventions, Comparisons and Outcomes
SIS: saline infusion sonography
TVUS: transvaginal ultrasound
Characteristics of studies awaiting assessment [ordered by study ID]
Clark 2014
Methods Randomised controlled multi-centre equivalence trial
Participants Abnormal uterine bleeding associated with a benign polyp.
Inclusion criteria:
1. Abnormal uterine bleeding requiring diagnostic micro-hysteroscopy
2. Finding of a benign polyp (glandulocystic or pedunculated/grade 0 fibroid) on diagnostic micro-hysteroscopy
3. No hysteroscopic features suspicious of malignancy
4. Need for polypectomy
Exclusion criteria:
1. Hysteroscopic features suggesting malignant lesion
2. Additional pathology necessitating hysterectomy
Interventions Outpatient polypectomy will be performed immediately following diagnosis at outpatient hysteroscopy in most
instances, although some participants may have their outpatient treatment scheduled to a later date, depending
upon local circumstances, within the following 8 weeks, as not all clinics are able to offer immediate “see & treat”
outpatient treatment. Polyp removal will be carried out under direct hysteroscopic vision using miniature mechanical
or electrosurgical instruments, with or without the need for minor degrees of cervical dilatation and local anaesthesia
(direct cervical infiltration or paracervical injection). Occasionally blind avulsion with small polypectomy forceps
after hysteroscopic localisation may be required
Inpatient polypectomy will be performed within 8 weeks of the initial diagnosis at outpatient hysteroscopy. Inpatient
polypectomy will be performed by traditional dilatation and endometrial curettage (’D&C’), blind avulsion with or
without prior localising hysteroscopy or under direct vision using an operative hysteroscope. In most instances, wide
dilation of the cervical canal will be required to accommodate the larger diameter inpatient instruments within the
uterus. General or spinal anaesthesia facilitates major degrees of cervical dilatation and manipulation of these larger
diameter instruments within the uterine cavity
Outcomes Primary outcome: The patient’s own assessment of bleeding symptoms at 6 months, using a dichotomous outcome
measure, will be used to establish if the treatment has been successful
Secondary outcome: The following secondary outcomes will be assessed by a booklet sent to the women at home
containing questionnaires/questions at baseline, 6, 12 and 24 months post-randomisation:
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Clark 2014 (Continued)
1. Shaw Menorrhagia assessment scale A multi-attribute utility, designed to measure the impact of heavy menstrual
bleeding (menorrhagia) upon HRQL
2. Likert scale. All patients will be asked how their bleeding has responded to treatment using a Likert scale with four
response options
3. Health-related quality of life measured by EuroQol EQ-5D Instrument
4. Visual analogue scale (VAS) It is now well established that objective measures of blood loss are not particularly
relevant to women’s subjective perception of bleeding symptoms
Notes Status of the trial: completed.
Query clarified by Dr Justin Clark on 08-12-2014:
“Our paper is just undergoing revision and should be published in the BMJ early next year.
Our full NIHR HTA report will be published shortly afterwards - publication being held until the BMJ paper is in.
I am unaware of any similar trials in female infertility - only MH Emanuel septoplasty trial and Dick Schoot RPOC
morcellation study”.
Moramezi 2012
Methods Randomisation: randomised; blinding: not blinded; placebo: not used; assignment: parallel
Participants Infertile patients aged 20 to 40 years who are candidates for IUI with normal hysterosalpingography
Exclusion criterion: ovarian hyperstimulation syndrome in patients suffering complications during surgery and
hysteroscopy
Interventions Intervention group: hysteroscopy
Control group: no hysteroscopy
Outcomes Primary outcome: pregnancy, diagnosed by ultrasound at 2 months after intervention
Secondary outcome: complications of hysteroscopy and treatment side effects of ovulation induction
Notes Recruitment status: completed.
The primary study author will be contacted.
HRQL: health-related quality of life
IUI: intrauterine insemination
Characteristics of ongoing studies [ordered by study ID]
Abiri 2014
Trial name or title The effect of hysteroscopy on successful pregnancy in IVF in the infertile women who are candidate for the
first IVF cycle
Methods Parallel-group randomised controlled trial
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Abiri 2014 (Continued)
Participants Inclusion criteria: age less than 38 years; BMI > 35, did not undergo hysteroscopy in the two past months,
absence of uterine and tubal pathology which is incurable by hysteroscopy, couples undergoing ART with
their own gametes.
Exclusion criteria: embryo Donation, oocyte donation, TESE, hypothalamic amenorrhoea, OHSS, severe
male factor, BMI < 35, hysteroscopy in past two months, age equal or more than 38 years, prior history of
IVF, uterine and tubal pathology which is incurable by hysteroscopy
Interventions Intervention 1: In the control group: no intervention will be done. Intervention 2: In the intervention group,
hysteroscopy is performed within 14 days prior to in vitro fertilisation and If there is an abnormality in the
uterine cavity, this will be correct at the same time
Outcomes Primary outcome: biochemical pregnancy. Timepoint: 2 weeks after IVF. Method of measurement: ßHCG
Secondary outcome:clinical pregnancy. Timepoint: 4 weeks after IVF. Method of measurement: vaginal
sonography
Starting date 24 May 2014
Contact information Amene Abiri
Infertility department, second floor, Shariati Hospital, Jalal al Ahmad avenue, Tehran
14114, Islamic Republic of Iran
Telephone: 00982184902421
e-mail: abiriir@ yahoo.com
Notes Recruitment status: completed.
Basma 2013
Trial name or title Hysteroscopy before first trial ICSI
Methods Parallel-group randomised controlled trial
Participants Primary infertility
Inclusion criteria: No previous IVF/ICSI cycle
Exclusion criteria: Antral follicle count (AFC) 4, Anti-mullarian hormone (AMH) ‘0.7, detectable uterine
pathology by ultrasound
Age minimum: 20 years
Age maximum: 40 years
Gender: Female
Interventions Not reported in the registered study protocol
Outcomes Primary outcome: clinical pregnancy with cardiac pulsation
Secondary outcome: abortion, implantation rate
Starting date 01 June 2013
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Basma 2013 (Continued)
Contact information Elsayedamr Basma
30 Garden City Smouha, Alexandria, Egypt
Telephone: 00201223106023
e-mail: elsayedamr@yahoo.com
Notes
Broekmans 2010
Trial name or title SIGnificance ofRoutineHysteroscopyPrior to a First ’inVitro Fertilization’ (IVF)TreatmentCycle - inSIGHT
ClinicalTrials.gov NCT01242852
Methods Multicentre, single-blind, parallel-group randomised controlled trial
Participants Women with primary or secondary infertility due to undergo IVF treatment with normal transvaginal ultra-
sound in the follicular phase of the menstrual cycle
Interventions Office hysteroscopy combined with a saline infusion sonography prior to a first IVF cycle compared to starting
IVF without prior hysteroscopy
Outcomes Primary: ongoing pregnancy
Secondary: costs, implantation rate, miscarriage rate and patient tolerance
Starting date Current status on 1 November 2012: recruiting
Contact information F.J. Broekmans, M.D., PhD
University Medical Center Utrecht, Utrecht the Netherlands 3584CX
Telephone: +31 887551041
e-mail: F.J.Broekmans@Umcutrecht.nl
Notes
El-Khayat 2012
Trial name or title Does office hysteroscopy and endometrial snip improve IUI outcome?: a randomized controlled trial
Methods Allocation: randomised; endpoint classification: efficacy study; interventionmodel: parallel assignment;mask-
ing: single-blind (participant); primary purpose: treatment
Participants Inclusion criteria: 18 to 38 years old, at least 1 patent tube, unexplained infertility or anovulation or mild to
moderate male factor infertility, previous failed IUI
Exclusion criteria: indication for ICSI
Interventions Control group: office hysteroscopy
Intervention group: office hysteroscopy and endometrial snip
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El-Khayat 2012 (Continued)
Outcomes Primary outcome: clinical pregnancy rate at 10 months
Secondary outcome: ongoing pregnancy rate at 12 months
Starting date Current status on 1 November 2012: recruiting since February 2012
Contact information Waleed El-Khayat, MD
Faculty of Medicine, Cairo University
Telephone: 23655215
e-mail: Waleed Elkhart@yahoo.com
Notes Status: recruiting.
Hare 2013
Trial name or title Hysteroscopy before in vitro fertilization - Does it improve the outcome?
Methods Parallel group randomised trial
Participants Inclusion Criteria: Women submitted to IVF or ISCI treatment, age > 18 years,able to read, speak and
understand Danish, written consent.
Exclusion Criteria: intrauterine abnormalities, infection, BMI > 35, known intrauterine cause to the infertile
condition,abuse of alcohol or drugs,untreated medical condition, pregnancy
Age minimum: 18 years
Age maximum: 40 years
Gender: Female
Interventions Office-hysteroscopy with biopsy
Outcomes pregnancy rates
[Time Frame: individual outcome will be evaluated within 8 weeks after IVF treatment. Over all outcome
will be evaluated after 3 years.]
Starting date January 2013
Contact information Kristine Juul Hare, MD, PhD
Hvidovre University Hospital, Danmark
e-mail: kjhare@dadlnet.dk
Notes Recruiting.
48Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Revel 2011
Trial name or title Safety study of use of hyaluronic acid gel to prevent intrauterine adhesions in hysteroscopic surgery
Methods Single-centre, parallel-group, randomised, single-blind controlled trial
Participants Women 18 years of age or older, undergoing hysteroscopic treatment
Interventions Application of hyaluronic acid gel (study group); the control intervention is not described
Outcomes Patient satisfaction following gel application at 2 months
Starting date Current status on 1 November 2012: not yet recruiting
Contact information Ariel Revel, MD
Hadassah Medical Organization
Telephone: 97226777111 ext 76389
e-mail: ariel2@hadassah.org.il
Notes
Sohrabvand 2012
Trial name or title Evaluation of diagnostic hysteroscopy findings in patients candidate for ART (IVF, ICSI) and its effect on
pregnancy rate compared to control group
Methods Randomisation: randomised; blinding: not blinded; placebo: not used; assignment: parallel; purpose: treat-
ment
Participants Inclusion criteria: hysterosalpingography normal during the past 12 months; normal vaginal ultrasound; age
between 25 and 40 years; absence of abnormal uterine bleeding and no hysteroscopy performed in the last 6
months
Interventions Control group: hysteroscopy is not done
In the intervention group a hysteroscopy is performed; submucosal myoma or polyps 1 cm or larger cervical
or uterine adhesions will be resolved
Outcomes Primary outcomes: presence of pathology
Secondary outcomes: pregnancy 14 days after embryo transfer
Starting date Current status on 1 November 2012: recruiting since June 2012
Contact information Farnaz Sohrabvand
Vali-e-Asr Reproductive Health & Research Center
Telephone: 00982166939320
e-mail: fsohrabvand@yahoo.com
Notes
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Weiss 2005
Trial name or title Endometrial hysteroscopy and curettage prior to embryo transfer
Methods Parallel group randomised study
Participants Inclusion Criteria: informed consent, in-vitro fertilisation candidate, normal blood coagulation.
Exclusion Criteria: anaemia (haemoglobin < 10 mg/dL), abnormal maternal karyotype, thrombocytopenia <
140,000, any contraindication to hysteroscopy or in-vitro fertilisation
Age minimum: 18 years
Age maximum: 35 years
Gender: Female
Interventions Hysteroscopy and curettage
Outcomes Primary outcomes: Endometrial receptivity, implantation rate and pregnancy rate
Starting date December 2005
Contact information Amir Weiss
HaEmek Medicak Center and Technion, Israel Institute of Technology
Telephone: 972-4-6494031
e-mail: weiss am@clalit.org.il
Notes Status: recruiting.
The first author will be contacted.
ART: assisted reproductive technology
ßHCG: beta human chorionic gonadotropin
BMI: body mass index
ICSI: intracytoplasmic sperm injection
IUI: intrauterine insemination
IVF: in vitro fertilisation
OHSS: Ovarian hyperstimulation syndrome
TESE: Testicular sperm extraction
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D A T A A N D A N A L Y S E S
Comparison 1. Operative hysteroscopy versus control in women with otherwise unexplained subfertility and
suspected major uterine cavity abnormalities
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical pregnancy 1 94 Odds Ratio (M-H, Fixed, 95% CI) 2.44 [0.97, 6.17]
1.1 Removal of submucous
fibroids only vs regular
fertility-oriented intercourse
1 52 Odds Ratio (M-H, Fixed, 95% CI) 2.04 [0.62, 6.66]
1.2 Removal of mixed
submucous-intramural fibroids
vs regular fertility-oriented
intercourse
1 42 Odds Ratio (M-H, Fixed, 95% CI) 3.24 [0.72, 14.57]
2 Miscarriage 1 30 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.12, 2.85]
2.1 Removal of submucous
fibroids only vs regular
fertility-oriented intercourse
1 19 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.09, 4.40]
2.2 Removal of mixed
submucous-intramural fibroids
vs regular fertility-oriented
intercourse
1 11 Odds Ratio (M-H, Fixed, 95% CI) 0.5 [0.03, 7.99]
Comparison 2. Operative hysteroscopy versus control in women undergoing MAR with suspected major uterine
cavity abnormalities
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical pregnancy 1 204 Odds Ratio (M-H, Fixed, 95% CI) 4.41 [2.45, 7.96]
1.1 Hysteroscopic
polypectomy vs diagnostic
hysteroscopy and biopsy only
prior to IUI
1 204 Odds Ratio (M-H, Fixed, 95% CI) 4.41 [2.45, 7.96]
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Analysis 1.1. Comparison 1 Operative hysteroscopy versus control in women with otherwise unexplained
subfertility and suspected major uterine cavity abnormalities, Outcome 1 Clinical pregnancy.
Review: Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities
Comparison: 1 Operative hysteroscopy versus control in women with otherwise unexplained subfertility and suspected major uterine cavity abnormalities
Outcome: 1 Clinical pregnancy
Study or subgroup
Operative
hys-
teroscopy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Removal of submucous fibroids only vs regular fertility-oriented intercourse
Casini 2006 13/30 6/22 66.2 % 2.04 [ 0.62, 6.66 ]
Subtotal (95% CI) 30 22 66.2 % 2.04 [ 0.62, 6.66 ]
Total events: 13 (Operative hysteroscopy), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
2 Removal of mixed submucous-intramural fibroids vs regular fertility-oriented intercourse
Casini 2006 8/22 3/20 33.8 % 3.24 [ 0.72, 14.57 ]
Subtotal (95% CI) 22 20 33.8 % 3.24 [ 0.72, 14.57 ]
Total events: 8 (Operative hysteroscopy), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 52 42 100.0 % 2.44 [ 0.97, 6.17 ]
Total events: 21 (Operative hysteroscopy), 9 (Control)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
0.01 0.1 1 10 100
Favours intercourse Favours myomectomy
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Analysis 1.2. Comparison 1 Operative hysteroscopy versus control in women with otherwise unexplained
subfertility and suspected major uterine cavity abnormalities, Outcome 2 Miscarriage.
Review: Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities
Comparison: 1 Operative hysteroscopy versus control in women with otherwise unexplained subfertility and suspected major uterine cavity abnormalities
Outcome: 2 Miscarriage
Study or subgroup
Operative
hys-
teroscopy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Removal of submucous fibroids only vs regular fertility-oriented intercourse
Casini 2006 5/13 3/6 63.5 % 0.63 [ 0.09, 4.40 ]
Subtotal (95% CI) 13 6 63.5 % 0.63 [ 0.09, 4.40 ]
Total events: 5 (Operative hysteroscopy), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
2 Removal of mixed submucous-intramural fibroids vs regular fertility-oriented intercourse
Casini 2006 4/8 2/3 36.5 % 0.50 [ 0.03, 7.99 ]
Subtotal (95% CI) 8 3 36.5 % 0.50 [ 0.03, 7.99 ]
Total events: 4 (Operative hysteroscopy), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 21 9 100.0 % 0.58 [ 0.12, 2.85 ]
Total events: 9 (Operative hysteroscopy), 5 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours myomectomy Favours intercourse
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Analysis 2.1. Comparison 2 Operative hysteroscopy versus control in women undergoing MAR with
suspected major uterine cavity abnormalities, Outcome 1 Clinical pregnancy.
Review: Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities
Comparison: 2 Operative hysteroscopy versus control in women undergoing MAR with suspected major uterine cavity abnormalities
Outcome: 1 Clinical pregnancy
Study or subgroup
Operative
hys-
teroscopy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hysteroscopic polypectomy vs diagnostic hysteroscopy and biopsy only prior to IUI
P rez-Medina 2005 64/101 29/103 100.0 % 4.41 [ 2.45, 7.96 ]
Total (95% CI) 101 103 100.0 % 4.41 [ 2.45, 7.96 ]
Total events: 64 (Operative hysteroscopy), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.93 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diagnostic only Favours polypectomy
A D D I T I O N A L T A B L E S
Table 1. Effect of polyp size on clinical pregnancy rates in the intervention group
Polyp size Clinical pregnancy1 Clinical pregnancy rate (95% CI)2
< 5 mm 19/25 76% (from 72% to 80%)
5 to 10 mm 18/32 56% (from 53% to 59%)
11 to 20 mm 16/26 61% (from 58% to 65%)
> 20 mm 11/18 61% (from 58% to 64%)
1 Clinical pregnancy is defined by a pregnancy diagnosed by ultrasound visualisation of at least one gestational sac per woman
randomised.
2 No significant difference was found for the clinical pregnancy rates between the 4 subgroups (P = 0.32).
54Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. GRADE evidence profile - unexplained subfertility and submucous fibroids
Quality assessment
Submucous fibroids and unexplained subfertility
No of studies Design Limitations Inconsistency Indirectness Imprecision Other considerations
Clinical pregnancy (follow-up 1 year; ultrasound1)
1 RCT Serious2 No serious inconsis-
tency
No serious indirect-
ness
Serious3 Reporting bias4
Miscarriage (follow-up 1 year; ultrasound5)
1 RCT Serious2 No serious inconsis-
tency
No serious indirect-
ness
Serious3 Reporting bias4
1 A clinical pregnancy was defined by the visualisation of an embryo with cardiac activity at six to seven weeks’ gestational age.
2 Unclear allocation concealment.
3 Wide confidence intervals.
4 High risk of selective outcome reporting and unclear whether there is other bias caused by imbalance in the baseline characteristics.
5 Miscarriage was defined by the clinical loss of an intrauterine pregnancy between the 7th and 12th weeks of gestation.
Table 3. GRADE evidence profile - endometrial polyps prior to IUI
Quality assessment
Endometrial polyps prior to gonadotropin and IUI treatment
No of studies Design Limitations Inconsistency Indirectness Imprecision Other considera-
tions
Clinical pregnancy (follow-up 4 IUI cycles; ultrasound1)
1 RCT No serious limita-
tions
No serious incon-
sistency
No serious indi-
rectness
No serious impre-
cision
Selective outcome
reporting2
1 Clinical pregnancy was defined by the presence of at least one gestational sac on ultrasound.
2 There was high risk for selective outcome reporting bias.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1MeSH descriptor Hysteroscopy explode all trees (328)
#2hysteroscopic near polypectom* (11)
#3hysteroscopic near polyp removal* (11)
#4hysteroscopic near synechiolys* (1)
#5hysteroscopic near synechiotomy (1)
#6hysteroscopic near adhesiolys* (5)
#7hysteroscopic near metroplast* (17)
#8hysteroscopic near septoplast* (5)
#9hysteroscopic near sept* resection* (10)
#10MeSH descriptor Infertility explode tree 2 (1,430)
#11endometri* near polyp* (118)
#12leiomyom* (588)
#13fibromyom* (28)
#14fibroid* (462)
#15fibroma* (56)
#16myoma* (370)
#17synechia* (196)
#18intrauterine OR uterine near adhesion* (2,918)
#19Asherman* near syndrome* (9)
#20intrauterine OR uterine near sept* (2,915)
#21intrauterine OR uterine disease* (4,621)
#22uterine neoplasm* (2,610)
#23intrauterine OR uterine near congenital abnormalit* (2,890)
#24intrauterine OR uterine near malformation* (2,900)
#25septate near uterus (23)
#26in vitro near fertil* (2,822)
#27ICSI (1,206)
#28IVF (2,740)
#29intracytoplasm* sperm in* (1,047)
#30IUI (456)
#31(uterine OR intrauterine) OR artificial near insemination* (10,282)
#32assisted reproduct* near technique* (363)
#33ART (73,076)
#34embryo transfer (1,918)
#35zygote intrafallopian transfer (40)
#36(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #6 OR #8 OR #9) (342)
#37(#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35) (85,110)
#38(#10 AND #36 AND #37) (37)
Search ’Trials’ (29)
29 records
Database: Cochrane Central Register of Controlled Trials : Issue 9 of 12, September 2014
Most recent update: 13 October 2014.
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Appendix 2. Cochrane Menstrual Disorders and Subfertility Group Specialised Register search
strategy
Keywords CONTAINS “hysteroscopic ”or “hysteroscopy”or “hysteroscope”or “endoscopy” or Title CONTAINS “hysteroscopic ”or
“hysteroscopy”or “hysteroscope”or “endoscopy”
AND
Keywords CONTAINS “subfertility”or “subfertility-Female”or “infertility” or “IVF” or “ICSI” or “IUI”or “in vitro fertilisation”
or “in vitro fertilization” or “Intrauterine Insemination” or “artificial insemination” or “assisted conception” or “assisted reproduc-
tion techniques” or “ embryo transfer” or “zygote intrafallopian transfer” or “myoma” or “myomas” or “myomectomy” or “septate
uterus”or “polypectomy” or“polyp removal” or “polyps”or “adhesiolysis”or “adhesion” or“adhesions” or“synechiotomy” or“Leiomyoma”
or“leiomyomata” or“fibroids” or“Asherman’s Syndrome”or “uterine septa”or “uterine septum” or“uterine disease”or “uterine leiomy-
omas” or“uterine malformation” or“Uterine Neoplasms”or “uterine polyps”
180 records
Database: Cochrane MDSG Specialised Register
Most recent update: 8 September 2014.
Appendix 3. MEDLINE search strategy (PubMed)
(“Hysteroscopy”[Mesh] OR Uterine Endoscop*[All Fields] OR Uteroscop*[All Fields] OR Hysteroscopic Surg*[All Fields] OR (hys-
teroscopic[All Fields] AND (polypectom*[All Fields] OR polyp removal*[All Fields] OR myomectom*[All Fields] OR synechioly-
sis[All Fields] OR synechiotomy[All Fields] OR adhesiolysis[All Fields] OR metroplast*[All Fields] OR septoplast*[All Fields] OR
septum resection*[All Fields]))) AND (Subfertility[tiab] OR “Infertility, Female”[Mesh] OR (female[tiab] AND (Infertility[tiab] OR
Sterility[tiab]))) AND (((“Endometrium”[Mesh] OR Endometri*[All Fields]) AND (polyp[All Fields] OR polyps[All Fields])) OR
“Leiomyoma”[Mesh] OR Leiomyoma[All Fields] OR Leiomyomas[All Fields] OR Fibromyoma[All Fields] OR Fibromyomas[All
Fields] OR Fibroid[All Fields] OR Fibroids[All Fields] OR fibromas[All Fields] OR Myoma[All Fields] OR Myomas[All Fields] OR
((Synechiae[All Fields] AND ((Intrauterine[All Fields] OR uterine[All Fields]) AND adhesion*)) OR “Asherman Syndrome”[All Fields]
OR “Asherman’s Syndrome”[All Fields] OR “Ashermans Syndrome”[All Fields] OR ((septa[All Fields] OR septum[All Fields]) AND
(uterine[All Fields] OR intrauterine[All Fields])) OR “Uterine Diseases”[Mesh] OR “Uterine Neoplasms”[Mesh] OR ((uterine[All
Fields] OR intrauterine[All Fields]) AND “Congenital Abnormalities”[Mesh]) OR “Fertilization in Vitro”[Mesh] OR (Fertilization[All
Fields] AND “in Vitro”[All Fields]) OR IVF[All Fields] OR ICSI[All Fields] OR “Reproductive Techniques”[Mesh] OR “Embryo
Transfer”[Mesh] OR “Zygote Intrafallopian Transfer”[Mesh] OR “Insemination, Artificial”[Mesh] OR ((intrauterine OR artificial)
AND insemination[All Fields]))) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR
placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh])
89 records
Database: MEDLINE using PubMed
Most recent update: 12 October 2014.
Appendix 4. EMBASE search strategy (Embase.com)
#1. ’hysteroscopy’/exp (7,918)
#2. hysteroscopy (8,686)
#3. ’endoscopy’ (184,646)
#4. ’endoscopy’/exp (416,527)
#5. ’infertility’/exp (92,710)
#6. ’subfertility’ (4,551)
#7. ’infertility’ (99,272)
#8. ’infertility therapy’/exp (79,750)
#9. ivf OR ’icsi’ (34,185)
#10. artificial AND insemination (14,748)
#11. assisted AND conception (3,939)
#12. ’uterus myoma’/exp (10,149)
#13. ’leiomyoma’/exp (14,378)
#14. myoma OR myomectomy (15,999)
#15. septate AND uterus (666)
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#16. ’polypectomy’ (8,683)
#17. ’adhesiolysis’ (1,803)
#18. ’polyp’ (48,672)
#19. uterine AND septa (223)
#20. ’uterine septum’ (351)
#21. synechiotomy (9)
#22. ’leiomyoma’ (17,645)
#23. ’uterine malformation’ (229)
#24. ’uterine anomaly’ (265)
#25. ’fibroid’ (3,694)
#26. OR (1-4) (457,395)
#27. OR (5-7) (118,016)
#28. OR (8-25) (183,344)
#29. AND (26-28) (3,184)
#30. #29 AND ([cochrane review]/lim OR [systematic review]/lim OR [controlled clinical trial]/limOR [randomized controlled trial]/
lim OR [meta analysis]/lim) (253)
253 records
Database: EMBASE using Embase.com
Most recent update: 7 October 2014.
Appendix 5. CINAHL search strategy (EBSCOHOST)
S1 TX hysteroscopy (391)
S2 TX uterine endoscop* (4)
S3 TX uteroscop* (1,001) Smart Text searching
S4 MH hysteroscopy (331)
S5 TX hysteroscopic polypectom* (4)
S6 TX hysteroscopic polyp removal* (13,517) Smart Text searching
S7 TX hysteroscopic myomectom* (16)
S8 TX hysteroscopic adhesiolys* (2)
S9 TX hysteroscopic synechiolys* (1,246) Smart Text searching
S10 TX hysteroscopic synechiotomy (1,246) Smart Text searching
S11 TX hysteroscopic metroplast* (7)
S12 TX hysteroscopic septoplast* (1)
S13 TX hysteroscopic septum resection (1)
S14 TX hysteroscopic sept* resection (3)
S15 TX subfertility (281)
S16 MHinfertility (3,706)
S17 TX sterility (361)
S18 MHfemale (776,980)
S19 TX endometri* polyp* (78)
S20 TX leiomyoma* (1,219)
S21 TX fibromyoma* (5)
S22 TX fibroid* (560)
S23 TX fibroma* (394)
S24 TX myoma* (169)
S25 TX synechia* (79)
S26 TX intrauterine adhesion* (11)
S27 TX uterine adhesion* (20)
S28 TX Asherman* syndrome (9)
S29 TX uterine sept* (18)
S30 TX intrauterine sept* (10)
S31 TX septate uterus (23)
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S32 MHuterine diseases (432)
S33 MH uterine neoplasm* (1,005)
S34 “”uterine congenital abnormalit*“” (19,260) Smart Text searching
S35 TX uterine congenital abnormalities (42,155) Smart Text searching
S36 TX uterine malformation* (29)
S37 MH Fertilization in vitro(1834)
S38 TX in vitro fertilisation (216)
S39 TX IVF (800)
S40 MHReproduction Techniques (1,945)
S41 TX ICSI (155)
S42 MHembryo transfer(350)
S43 MH Gamete Intrafallopian Transfer (55)
S44 MH Insemination, Artificial (301)
S45 TX intrauterine insemination (97)
S46 TX IUI (50)
S47 MH Clinical Trials“# OR #MH ”Randomized Controlled Trials# (502,384) SmartText Searching
S48 PT clinical trial* (51,468)
S49 PT Randomized Controlled Trials (181,244)
S50 MH Randomized Controlled Trials (20,360)
S51 TXrandomised controlled trial (6,360)
S52 PT randomised controlled trial* (118,899) SmartText Searching
S53 MH Random Assignment (31,296)
S54 TX Randomi*ation (3,619)
S55 MH Single-Blind Studies (6,144)
S56 MH Double-Blind Studies (20,422)
S57 MH Triple-Blind Studies (65)
S58 TX treble blind* (34,072) Smart Text searching
S59 MH Placebos (7,082)
S60 MH Prospective Studies (162,939)
S61 OR/S47-60 (631,229)
S62 OR/S1-14 (13,795)
S63 OR/S15-17 (4,227)
S64 S18 AND S63 (2,550)
S65 0R/S19-46 (46,874)
S66 S61 and S62 and S64 and S65 (21)
21 records
Database: CINAHL using EBSCOHOST
Most recent update: 11 October 2014.
Appendix 6. Web of Science search strategy (WoS Core Collection)
TS=((((Hysteroscopy OR Uterine Endoscop* OR Uteroscop* OR Hysteroscopic Surg* OR (hysteroscopic AND (polypectom* OR
myomectom* OR synechiolysis OR adhesiolysis OR metroplast* OR septoplast* OR septum resection*))) AND (female AND (Sub-
fertility OR Infertility OR Sterility)) AND ((Endometri* AND (polyp OR polyps)) OR Leiomyoma* OR Fibromyoma* OR Fibroid*
OR fibromas OR Myoma* OR Synechiae OR ((Intrauterine OR uterine) AND adhesion*) OR (Asherman* AND Syndrome*) OR
((septa OR septum) AND (uterine OR intrauterine)) OR uterine diseases OR uterine neoplasms OR ((uterine OR intrauterine) AND
(congenital abnormalities)) OR (Fertilization SAME “in Vitro”) OR IVF OR ICSI OR reproductive techniques OR embryo transfer
Or zygote intrafallopian transfer OR ((intrauterine OR artificial) AND insemination))))) (70)
70 records
Database: Web of Science Core Collection Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
Most recent update: 11 October 2014.
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Appendix 7. Items of data extraction
1. Source
1. Study ID
2. Report ID
3. Review author ID
4. Citation and contact details
2. Eligibility
1. Confirm eligibility for review
2. Reason for exclusion
3. Trial characteristics
1.Study design
• Random sequence generation
• Patient recruitment
• Patient in- and exclusion criteria
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessors
• Completeness of outcome data
• Selective outcome reporting
• Other potential sources of bias
2. Follow-up
• Duration of follow-up
• Type of follow-up
3. Size of study
• Number of women recruited
• Number of women randomised
• Number of women excluded
• Number of women withdrawn and lost to follow-up
• Number of women analysed
4. Study setting
• Single-centre or multicentre
• Location
• Timing and duration
5. Diagnostic criteria
• Screening by TVS
• Screening by HSG
• Screening by TVS and HSG
• Screening by other ultrasound diagnostic procedures, e.g. SIS or GIS
• Screening by hysteroscopy
• Diagnosis confirmed by hysteroscopy and biopsy
4. Characteristics of the study participants
1. Baseline characteristics
• Age
• Primary or secondary subfertility
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• Duration of subfertility
• Diagnostic work-up: baseline FSH, semen analysis, diagnosis of tubal pathology, confirmatory test of ovulation
• Other contributory causes to subfertility than uterine factor
• Previous treatments - IVF, IUI or other treatments
2. Treatment characteristics
• IUI natural cycle
• IUI controlled ovarian stimulation with anti-oestrogens or gonadotropins
• IVF protocol and number of embryos transferred
• ICSI protocol and number of embryos transferred
• detailed description of the hysteroscopic procedure
5. Interventions
• Total number of intervention groups
• Absence of other interventions in the treatment and control group
For each intervention and comparison group of interest:
• Specific intervention
• Intervention details
• Timing of the intervention
6. Outcomes
• Outcomes and time points collected
• Outcomes and time points reported
Definition and unit of measurement for each of the following outcomes:
Primary outcome:
• Live birth delivery rate
• Hysteroscopy complication rate
Secondary outcome:
• Ongoing pregnancy rate
• Clinical pregnancy with fetal heart beat
• Clinical pregnancy rate
• Miscarriage rate
For each outcome of interest:
• Sample size
• Missing participants
• Summary data for each intervention group in 2 x 2 table
• Estimate of effect with 95% CI
• Subgroup analyses
7. Miscellaneous
• Funding source
• Key conclusions of the study authors
• Miscellaneous comments from the study authors
• References to other relevant studies
• Correspondence required
• Miscellaneous comments by the review authors
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WH A T ’ S N E W
Last assessed as up-to-date: 8 September 2014.
Date Event Description
29 October 2014 New citation required but conclusions have not
changed
There was no change to our conclusions.
29 October 2014 New search has been performed This review has been updated but no new studies were
eligible for inclusion
H I S T O R Y
Protocol first published: Issue 11, 2011
Review first published: Issue 1, 2013
Date Event Description
29 August 2014 Feedback has been incorporated Feedback on clinical diversity in this review, received from Professor Hossam
Shawki
C O N T R I B U T I O N S O F A U T H O R S
JB co-ordinated the writing of the protocol and review and its update.
JK co-authored the protocol for the background section and searched the literature.
FB and TD independently assessed the retrieved published reports for inclusion of potentially eligible studies.
SW independently extracted study data.
BWM gave advice on review methodology and content and critically appraised the Cochrane review.
D E C L A R A T I O N S O F I N T E R E S T
FB and JK (principal investigator) and BWM (co-investigator) are at present involved in the ’inSIGHT trial’ (SIGnificance of Routine
Hysteroscopy Prior to a First ’in Vitro Fertilization’ Treatment Cycle: NCT 01242852), which is financially supported by ZonMw, a
Dutch government operated consortium responsible for granting funds in the field of clinical practice research. This study is still in
the recruitment phase.
The first published version of the present Cochrane review has been part of a PhD thesis entitled “Studies on the effectiveness of
endoscopic surgery in reproductive medicine” (http://dare.uva.nl/record/497164), which has been successfully defended at the faculty
of Medicine of the University of Amsterdam, the Netherlands on 2 September 2014 by the first author (JB).
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S O U R C E S O F S U P P O R T
Internal sources
• CEBAM, Belgium.
Research grant was obtained through CEBAM, the Centre for Evidence-based Medicine, Belgian Branch of the Cochrane
Collaboration
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. As a result of further peer review, the objectives of the review have been rephrased. The descriptions in the Types of interventions
and Data synthesis sections were modified accordingly. For both comparisons we made a stratification according to the types of
uterine pathology; for the second comparison we made a clear distinction between IUI, IVF or ICSI.
2. A ’Summary of findings’ table using the GRADE approach has been added.
3. In the Assessment of risk of bias in included studies section of the review, the items ’blinding of participants and personnel’ and
’blinding of outcome assessors’ were reinserted as requested by the editorial reviewers. We assessed all six items including blinding of
participants, personnel and outcome assessors in the final review as opposed to the protocol.
4. In the Assessment of heterogeneity section of the review we have added the Q-statistic.
5. In the Subgroup analysis and investigation of heterogeneity section of the review we planned to conduct a further subgroup
analysis based on the women’s age.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Hysteroscopy; Coitus; Endometrium; Fertilization inVitro; Infertility [etiology; ∗surgery]; Insemination, Artificial [methods]; Leiomy-
oma [surgery]; Polyps [surgery]; Randomized Controlled Trials as Topic; Tissue Adhesions [surgery]; Uterine Diseases [∗surgery];
Uterus [abnormalities]
MeSH check words
Female; Humans; Pregnancy
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